Synthesis of peptides by the solid phase method by Roach, Peter L.
Synthesis of Peptides by the Solid Phase Method 
Peter L. Roach 
Doctor of Philosophy 
University of Edinburgh 
1990 
This thesis is submitted in part fulfilment of the requirements of the degree of Doctor of 
Philosophy in the University of Edinburgh. Unless otherwise stated the work described is original 
and has not been previously submitted, in whole or in part, for any degree at this or any other 
university. 
University of Edinburgh 
October 1990 
Acknowledgements. 
I would like to thank Professor R. Ramage for his patience, guidance and encouragment 
throughout the course of this work. 
I wish to thank Mr. K. Shaw and Mr. B. Whigham for their technical assistance. I would 
like to express my thanks to those involved in the departmental analytical and spectroscopic 
services for their efficient work. I also thank Laporte Fine Organics for provision of a research 
grant. 
would like to thank Drs. C. Bladon, T. Brown, J. Parkinson and D. W. Thomas and Mr. 
D. Camp for proofreading and helpfuldiscussions. Finally, I would liketothank my family, friends 
and colleagues who helped to make my time in Edinburgh so enjoyable. 
To my parents, Peter and Lucille 
and my sister, Sherry. 
ABSTRACT 
An investigation into the use of a novel NU  protecting group in peptide synthesis is 
described. The protecting group, 2,2-bis(4'-nitrophenyl)ethoxycarbonyl (Bnpeoc), has been 
introduced into the full range of amino acids, including those requiring appropriate side chain 
protection. 
The Bnpeoc amino acid derivatives have been successfully applied to the solid phase 
synthesis of a number of peptides from ubiquitin. In addition, the peptides were assembled using 
a wide range of coupling reagents and conditions. 
The chemical syntheses of phage ? Cro protein and peptides from its DNA binding region 
have also been investigated, using both the novel NaBnpeoc  protecting group and the 
established Nafluorenylmethoxcarbonyl  (Fmoc) protecting group. 
N.m.r. experiments have indicated that residues corresponding to the DNA recognition 
a-helix of the Cro protein may adopt a similar conformation in a peptide from that region. 
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Abbreviations. 
Bnpeoc 2, 2-bis(4'-Nitrophenyl)ethoxycarbonyl 
Boc Butyloxycarbonyl 
BOP Benzotriazole-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate 
Bpoc Biphenylpropyloxycarbonyl 
Cbz, Z Benzyloxycarbonyl 
CM Carboxymethyl 
COSY Correlated spectroscopy 










EDT 1 ,2-Ethanedithiol 
ex. Exchangable with solvent 
F.A.B. Fast atom bombardment 
Fmoc Fluorenylmethoxycarbonyl 
HBTU 2-( I -Hydroxy-1 ,2,3-benzotriazol-1 -yl)-1 , 1 ,3,3-tetramethyluronium 
hexafluorophosphate 
HFI P Hexafluoroisopropanol 
h.p.l.c. High performance liquid chromatography 
hrms High resolution mass spectrometry 
HOBt 1 -Hydroxy-1 ,2,3-benzotriazole 
HTH Helix-turn-helix 
Mbh 4,4'-Dimethoxybenzhydryl 
Mtr Methoxytrimethylbenzene suiphonyl 
NMM N-Methylmorpholine 
nOe Nuclear Overhauser enhancement 
NOESY Nuclear Overhauser Enhancement Spectroscopy 
PAM Phenylacétamidomethyl 
Pmc 2,2,5,7,8-Pentamethylchroman-6-sulphonyl 
Sasrin Super acid sensitive resin 
SOS PAGE Sodium dodecyl sulphate poylacrylamide gel electrophoresis 
SPPS Solid phase peptide synthesis 
TBTU 2-( 1 -Hydroxy-1 ,2,3-benzotriazol-1 -yl)-1 1 ,3,3-tetramethyluronium 
tetrafluonborate 
TEA Triethylamine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 





Conventionally genes are indicated by an italic abbreviation (e.g. Cro, ci, Antp). The 
protein products of these genes are indicated by the use of Roman letters (e.g. Cro, lac, 
Antp). 
Bacteriophage A virus which infects bacteria. 
Lysogeny The incorporation of viral DNA into the host bacterial chromosome 
Lytic Cycle The reproduction of many viral particles until the bacterial host cell bursts. 
Operator An area of DNA to which one or more repressor proteins may bind in order to 
prevent transcription (and hence expression) of a gene. 
Operator Site The small region(s) of DNA within an operator to which the repressor binds. 
Promoter A region of DNA to which RNA polymerase binds to initiate transcription. 




1.1 Solid Phase Peptide Synthesis 
1.1.1 Historical perspective. 
The diverse range of functional groups found in peptides and proteins, often arrayed in 
complex structures, makes them ideally suited to the enormous range of biological functions 
which they perform. Yet it is this diversity of functional groups that has challenged the organic 
chemist with many interesting problems since the turn of the century. 
Theodor Curtius (1857-1928) was perhaps the first to synthesise a peptide derivative, 
hippurylglycine 1 , but it was the pioneering work of Emil Fisher (1852-191 9) which led to the 
isolation of the first free peptide 2 , glycylglycine, in 1901. Some six years later, Fisher was able 
to report3 the preparation of a sixteen residue peptide. All this was achieved at a time when the 
nature of peptides and particularly proteins was still in some doubt. 
In his original work, Fisher had used ethyichloroformate to protect the amino function as 
a urethane. Urethanes remain the principle method of amine protection during peptide synthesis 
to this day. However, his efforts to remove this protection were unsuccessful. The next major step 
forward in peptide synthesis was to be the development of a reversible amino protecting group, 
by Bergmann and Zervas 4 in 1932. They described the preparation of a number of Ncx 
benzyloxycarbonyl amino acid derivatives which could readily be deprotected by hydrogenolysis 
with palladium on charcoal as a catalyst. This has been applied to a wide range of solution 
syntheses with great success 56 : 
Much of the early work had been directed towards the synthesis of proteins, but it was 
the emerging nature of the peptide hormones and antibiotics that provided organic chemists in 
the late 1940s and 1950s   with viable synthetic targets. The isolation, structure and total synthesis 
of oxytocin, a lactogenic nonapeptide amide hormone, by du Vigneaud Ct aL 5  showed the great 
potential of the solution phase synthesis of peptides. However, the isolation of increasing 
numbers of peptide hormones and the increasing complexity of the sequences began to indicate 
the limitations of solution synthesis: the syntheses were both laborious and time consuming. 
In 1963, with these problems clearly in mind, Merrifield introduced 7 solid phase peptide 
synthesis. Within a year, he reported 8 the synthesis of bradykinin, a nonapeptide amide, which 
was prepared in an overall yield of 32 1/6 in only eight days. This was much fasterthan was possible 
by solution methods. Merrifield began by attaching an Naprotected  amino acid derivative to a 
polystyrene based solid support, through the carboxylic acid group, then deprotecting the N 
terminus and coupling the next Naprotected  amino acid to it. He then extended the chain, one 
residue at a time, in a stepwise process of activation, coupling and deprotection. The concept 
revolutionised peptide synthesis and had a profound effect on the development of methods to 
synthesise oligonucleotides. 
3 
1.1.2 The Strategy of Solid Phase Peptide Synthesis. 
The solution phase synthesis of peptides containing more than a few residues is often 
slow and painstaking work. The solid phase approach has a number of advantages: 
It avoided the loses normally associated with the isolation and purification of all the 
intermediates in solution phase synthesis. 
Individual reactions can be forced to completion by the use of large excesses of the 
reagent. These can be easily removed by washing the peptidyl resin. 
The repetitive synthetic cycle lends itself readily to automation; modern automated 
synthesisers assemble peptides much more rapidly, often adding one residue every three or four 
hours. 
The use of a single vessel reduces mechanical losses which typically occur with the 
repeated transfer of material. 
The strategy9  is outlined in scheme 1 and descibed below. The insoluble support 
is a synthetic polymer or 'resin' which contains reactive groups (L'). The C-terminal Nap rotected 
residue is firstly activated by some appropriate chemistry (A) and then coupled to the polymer. 
The Naprotecting  group is chosen so that its subsequent removal does not interfere with either 
the link to the polymer (L) or the semi-permanant protecting groups (S) on functional groups of 
the amino acid side chains (R). Once the N 11 protecting group has been removed, the next 
activated Naprotected  amino acid derivative is coupled. The cycle of deprotection and coupling 
is then repeated, increasing the number of residues (n) until the peptide chain is complete. The 
side chain protecting groups (S) may then be removed and the peptide resin link (L) cleaved. 
These are often chosen so that they are cleaved by the same reagent, but these steps may be 
carried out sequentially if the nature of the peptide resin link and the side chain protection permit. 
There have been two major applications of this strategy. The first was the 'graded 
acidolysis' method which was used originally by Merrifield 8. The side chain protection and peptide 
resin link were cleaved by strong acids (such as HF and trifluoromethanesuiphonic acid) and for 
the N-terminal protection the Boc group was used and cleaved by TFA. The other principle 
method is the orthogonal strategy developed by Sheppard 10 ' 11 . In this method the N-terminal 
protection is the Fmoc group 12 which is cleaved with piperidine in DMF. This does not effect the 
side chain protecting groups and peptide resin link which are both labile to milder acid (TFA). The 
concept of orthogonality, in which the conditions used to cleave each of more than one set of 









P-NH 	 + 	L'-Polymer 
0 
P-(NC0)-L-Polymer 
Coupling 	 ) Deprotection 
H-(NHC0)-L-PoIymer 
Cleavage 
H-(N H- ' C0)H 
Scheme 1. The strategy of solid phase peptide synthesis. 
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1.1.3 The Solid Support 
The solid support has a number of requirements 13 : 
Reactive sites that provide an attachment point for the peptide, from which it can later 
be removed. This mustbe stable to the conditions of synthesis. 
The support must allow rapid and unhindered contact between the growing peptide 
chain and the reagents. This is usually achieved by swelling the polymer matrix in an appropriate 
solvent. 
The polymer must be composed of particles that allow ready manipulation and rapid 
filtration of liquids. 
The support selected by Merrifield was gelatinous polystyrene beads made of a co-
polymer obtained from 2% divinylbenzene in styrene 7. More cross linking (e.g. 8 or 16% 
divinylbenzene) 7 lead to rigid, less permeable beads, whilst less cross linking. (e.g. 0.5% 
divinylbenzene) 14 leads to soft beads, for which filtration can no longer be used as a method of 
separation. 
In solution synthesis, if the growing peptide chain is not adequately solvated it may 
aggregate and this often results in an insoluble precipitate. On the solid phase support, such 
aggregation is more difficult, but can still occur and causes the internal collapse of the resin. This 
led Sheppard 15 to develop the concept of a polar matrix and solvent. The excellent solvating 
properties of DMF were well known from solution phase syntheses and made it an excellent 
solvent for solid phase synthesis. For a solid phase he chose polyamide resins, which swell very 
well in DMF and have a 'peptide-like' character 16 ' 17. The use of polyamide resin as the solid 
support and DMF as the solvent has been successfully applied in commercially available 
automated synthesisers. Both polystyrene and polyamide supports have seen widespread use. 
1.1.4 The peptide resin linkage. 
The most common method for attaching the peptide to the resin is through a benzyl ester. 
The earliest methods used by Merrifield involved the chioromethylation of the resin, as shown 
in scheme 2. The chloromethylation of the resin produces an aryichioromethyl derivative (1), 
which, upon reaction with the tnethylammonium or caesium salt of the C-terminal amino acid 
derivative, gives a benzyl ester linkage. 
19 
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Scheme 2. Attachment of the first amino acid to the resin. 
The N-terminal group used by Merrifield in the bradykinin synthesis 8 was tert.butyl-
oxycarbonyl, which was removed by treating the peptidyl resin with 50% trifluoroacetic acid in 
dichioromethane. The benzyl ester was not entirely stable to these conditions and this led to a 
steady 'bleeding' of about 1.5% of the peptide from the resin per cycle. For bradykinin, with only 
nine cycles, this was acceptable, but as more ambitious syntheses were undertaken, this became 
increasingly significant. An electron withdrawing group introduced para to the benzyl ester should 
increase its acid stability and this was the principle behind the design of the phenylacet-
amidomethyl (Pam) resin, developed by Merrifield etal. 1819 
In an effort to circu mvent the vigorous conditions required for cleavage and deprotection 
used in the Merrifield method, the very acid labile Bpoc2° and the base labile Fmo& 2 amino 
terminal protecting groups were introduced. This required a linker of greater acid lability. The p-
alkoxybenzyl alcohol resin (2) was originally developed by Wang 21 (scheme 3) for the synthesis 
of protected fragments. It has been widely adopted for use in the Fmoc strategy of solid phase 
peptide synthesis and the mechanism for its cleavage by trifluroacetic acid and water (95:5) is 
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Scheme 4. The cleavage of the Wang linker by acid. 
Fi 
A further development has been the extension of orthogonality into a third 
dimension with the introduction of fluoride labile linkers. The linkers developed by Barany(3) and 
Ramage(4) rely on the attack on a silicon centre by fluoride and both linkers allow the cleavage 
of the protected peptide from the resin under neutral conditions (e.g. using tetrabutylammonium 
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The preparation of C-terminal peptide amides requires the use of a different linker. 
Recently a number of examples of these have been developed for use in the Fmoc strategy 24 '25 . 
The dibenzosuberanyl derivative (5) has been developed in this research group and applied to 







Figure 1. Linker for the preparation of peptide amides using the Fmoc strategy. 
DI 
1.1.5 NcI protecting groups. 
The Nuprotecting  groups which are most widely used in peptide synthesis are urethane 
derivatives, in which the urethane ester moiety is first cleaved, with subsequent loss of carbon 
dioxide from the resulting carbamate, giving the unblocked amine. 
The benzyloxycarbonyl (Z or Cbz) group. 
0rO)~  
(6) 
The first reversible NU  protecting group was the benzyloxycarbonyl or Z protecting group 
(6), which was introduced by Bergmann and Zervas 4 in 1932. The principle methods of cleavage 
are hydrogenolysis with palladium on charcoal as a catalyst, or acid catalysed solvolysis using 
HBr in acetic acid. A wide variety of substitutions on the aromatic ring have been investigated 28 
in order to vary the acid lability of the protecting group. 
The tert. butyloxycarbonyl (Boc) group. 
(CH3)3C 
 "% 0 "'k 
(7) 
This protecting group (7) was an essential element of the Merrifield 'graded acidolysis' 
strategy8  and is still the most popular acid labile NI protecting group used for solid phase peptide 
synthesis. Cleavage is usually achieved with a solution of trifluoroacetic acid in dichloromethane 
(1:1). The mechanism of cleavage, shown in scheme 5, includes the generation of a carbonium 
ion (8), which.is a very reactive alkylating species and can cause problems with any sulphur 
containing residues (Met and Cys) and some of the aromatic amino acids (Tyr and Trp). The use 










Side 	OMe 	c02 + NH2-R 
Reactions  
C(CH3)3  
Scheme 5. The cleavage of the Boc group by acid. 
c). f3-Eliminating Protecting Groups. 
Base labile protecting groups have been used in natural product synthesis for many 
years. In solid phase peptide synthesis, the most widely used group has been the 9-
fluorenylmethoxycarbonyl (Fmoc) group, which was introduced by Carpin& 2 and applied to 
peptide synthesis by Sheppard10' 11, 
The incorporation of a base labile NU  protecting group allows the linker and side chain 
protection to be cleaved using rather milder acid conditions than those required by Merrifield 8 . 
The cleavage of the Fmoc group is usually carried out with 20% (vlv) piperidine in DMF which 
allows the olefin (9), which is initially produced by n-elimination, to be trapped as its piperidine 






CO2 + NHR 
Scheme 6. The cleavage of the Fmoc protecting group by piperidine. 
Recently, Carpino et al. 3°  have introduced the 2-chloro-3-indenylmethoxycarbonyl 
(Climoc) (11) and benz[f ]inden-3-ylmethoxycarbonyl (Bimoc) (12) groups, (shown in figure 2). 
These were applied to peptide synthesis, but using an adapted solid phase approach. The peptide 
remained in solution but the active ester required for coupling and the base used for deprotection 
were both attached to solid supports. The Climoc group was not completely stable in a DMF 
solution, but a tetrapeptide, Climoc-Gly-Gly-Phe-Leu-OBzl was assembled in dichloromethane 
from H-Leu-QBzl in 74% yield. With the Bimoc group the sequence Fmoc-Tyr(OBzl)-Gly-GIy-
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(13) 	 (14) 
Figure 2. The structures of n-eliminating protecting groups: Bimoc (11), Climoc (12) and 
Bnpeoc (13) and Teoc (14) protecting groups. 
Another recently introduced base labile protecting group is the 2,2-bis(4'-
nitrophenyl)ethoxycarbonyl (Bnpeoc) protecting group (13)3132.  This group can be cleaved in 
20% piperidine in DMF, in a similar fashion to Fmoc and has been used to assemble two small 
test peptides, H-Leu-1 le-Phe-AIa-Gly-OH and H-Thr-Leu-Ser-Ile-Gly-0H 33 . 
The 3-(trimethylsilyl)ethoxycarbonyl (Teoc) protecting group (14) developed by Carpino 
et aI.34 is an elegant development of the f-eliminating amino protecting group and has been 
applied to peptide synthesis 35. It is cleaved by fluoride, as shown in scheme 7, with n-elimination 
of the silyl moiety. It can also be cleaved by anhydrous TFA. 
13 
Me3SK&9 
- 	 NH-R 
F 
Me3SiF + CH2==CH2 + 	OQffC:R 
CO2 +NHR 
Scheme 7. The cleavage of the Teoc (14) protecting group by fluoride. 
1.1.6 Side chain protection. 
The use of Boc as the Nx  protecting group in the Merrifield strategy precludes the use of 
any side chain protection which is cleaved to a significant extent by 50% TFA in dichioromethane. 
Most protecting groups used with this strategy are based on the benzyl group and the derivatives 
typically used are shown in table 1. 
In the Fmoc strategy, the more acid labile tert.butyl derivatives can be used for most side 
chain protecting groups, although some amino acids require special consideration. Arginine can 
be protected with the pentamethylchroman sulphonyl protecting group 36 to provide acid lability 
which is comparable to Bu' esters and ethers. This has been applied to a number of successful 
syntheses37. 
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Residue Boc strategy Fmoc strategy 
Asp, Glu OBzI, OcHxI Bu t 
Ser, Thr Bzl Bu t 
Lys 2C1-Z Boc 
His it-Born, t-Dnp n-Bum, t-Trt 
Arg los, NO2 , Mts Pmc 
Tyr BrZ Bu t 
Trp Formyl None 
Table 1. Side chain protecting groups that are often used for solid phase peptide 
synthesis in the Boc and Fmoc strategies (adapted from ref. 9). 
Thecarboxamido group of asparagine and glutamine have often been left unprotected 
during peptide synthesis, but they can undergo dehydration during activation and coupling to give 
f-cyanoalanine and y-cyanobutyrine respectively. The formation of these derivatives has been 
observed with several coupling reagents, including DCCI, phosphoryl chloride and during the 
use of phosgene to generate N-carboxyanhydrides 39. The mechanism for this process is not 
obvious39 '40 but a hypothetical mechanism is shown in scheme 8. 
H 	 H 
X Y 	 X + Y + 
CN + O—X + W 
Scheme 8. A mechanism for the dehydration of Asn and GIn residues during activation 
and coupling. 
The formation of these derivatives can be prevented by the use of acid labile alkyl 
protecting groups on the carboxamido group. The N-bis(4-methoxy)methyl (Mbh) 41 (15) and N-
trityl (Trt) 42  (16) derivatives, shown in figure 3, have been used successfully. However, these large 
protecting groups reduce the solubility of the derivatives in some solvents and also may slow the 









Figure 3. The protection of asparagine (n=1) and glutamine (n=2) with Mbh (15) and Trt 
(16). 
The protection of the suiphydryl group of cysteine residues is necessary as it is 
a potent nucleophile and can be acylated to form a thioester or be oxidised, even by air, to a 
disulphide. Several protecting groups have been used for sulphydryl protection and the groups 
chosen depend on whether the final target molecule has a free thiol or one or more disuiphide 
bridges. In the case of multiple disuiphide bridges, the selective formation of these depends on 
the orthogonality of protection used for pairs of residues. 
1.1.7 Coupling methods. 
The coupling of amino acids is the most frequent point of failure in solid phase peptide 
synthesis. An ideal coupling reagent has several important features: 
1). It must be easy to handle and manipulate on an automated synthesiser. 
2) It must not allow racemisation to occur. 
3). It must give rapid and efficient coupling. 
Some of these requirements are, to some extent, mutually exclusive. For example, 
reagents which couple most rapidly are often air or moisture sensitive and therefore difficult to 
handle. Some of the methods of coupling amino acids in peptide synthesis are discussed below. 
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The Azide Method. 
Developed by Curtius, the azide coupling method has been widely and successfully 
used in the solution phase synthesis of peptides 6. As can be seen in scheme 9, acyl hydrazides 
were originally prepared by treating an alkyl ester (17) with hydrazine and then treating the 
resultant hydrazide(18) with nitrous acid to give the acyl azide (19). These methods have been 
improved by the introduction of alkyl nitrites to convert the hydrazide to an azide. 
RO-CH3  NH2NH2 	Ry..NHNH2 
Y 
(17) 	 (18) 
HONO A N=N=N 
0 
(19) 
Scheme 9. The preparation of acyl azides. 
The main problem with this coupling method is the side reaction of acyl azides, the 
Curtius rearrangment. This side reaction is promoted by heating and by the presence of Lewis 
or protic acids. Azide couplings are therefore usually performed at low temperatures and in high 
concentration, immediately after preparing the azide. 
Acid Chlorides 
Acid chlorides have a long history of use in solution phase synthesis of peptides, but have 
been little used in solid phase work. One reason for this is undoubtedly the tendency of the 
protected amino acid chlorides to form azlactones, with the concomitant risk of racemisation 
during activation and coupling. However, Carpino etaL 44 have shown the long term stability and 
superior reactivity of Fmoc amino acid chlorides and suggested that problems of racemisation 
with Fmoc protected amino acid chlorides are remarkably low (less than 0.1% loss of chirality). 
Symmetrical anhydrides. 
These are often prepared using carbodiimides 45, as shown in scheme 10. Originally 
dicyclohexylcarbodiimide was used, but the superior solubility of the reaction by-products from 
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Scheme 10. The formation of a symmetrical anhydride (20) using a dialkylcarbodiimide. 
While these reagents have enjoyed considerable success in both the Boc 4647 and 
Fmoc 49 stratagies, there are a number of problems associated with their use. Dichioromethane, 
which provides nearoptimal conditions of activatiOn 50 ' 51 is not a particularly good solvent for some 
of the Fmoc amino acids, or for some of the newly formed symmetrical anhydrides 52 . These 
derivatives are sometimes slow to couple, particularly when the anhydnde is prepared from an 
amino acid derivative with a stericafly bulky side chain and is to be coupled to a hindered amino 
component (e.g. Leu, lIe, or Val residues). The highly activated 0-acyl urea which is initially 
formed can undergo rearrangement to the unreative N-acyl urea and cannot then couple. Finally, 
the symmetrical anhydride method wastes more than half of the (often expensive) protected 
amino acid denvative. 
18 
d). Active ester methods. 
The formation of a peptide bond by the aminolysis of an ester dates from the work of 
Schwyzer et al. 51  who investigated the reaction of modified hippuric acid methyl esters (21). 
H O % X 
(21) 	 X = electron withdrawing group 
The development of aryl esters for peptide synthesis, such a p-nitrophenyl esters, was 
applied successfully to the solution phase synthesis of oxytocin 54 in 1959. Since then, a wide 
variety of alcohol components, for the preparation of active esters, have been examined 55 and 
applied with varying success. 
In a somewhat similar vein are the 0-acyl derivatives of substituted hydroxylamines.The 
superior reactivity of these derivatives is thought to be caused by the anchimeric assistance 
provided by the nitrogen atom. An example, using the popular 1-hydroxybenzotriazole ester, is 
shown in scheme 11. 
H' 
	






Scheme 11. The formation of a peptide bond by an HOBt ester 
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These compounds can be used either as an additive in a catalytic concentration in 
combination with another method of activation, or in stoichiometric quantities. A number of 
methods have been used to prepare these active esters. The use of dialkylcarbodimides is a 
common method. More recently they have been prepared from benzotriazoIyloxy-tris(dimeth,1)amino-
phosphonium hexafluorophoshate (BOP reagent) (22) of Castro et aL57 which has been 
successfully applied to peptide synthesis. Knorr etal.59 have used the somewhat similar 2-(1-














	 e). Mixed Anhydrides. 
The use of mixed or unsymmetrical anhydrides (24) has been the subject of active 
research for many years 60 ' 61 
R< 	R—( 	 R—( 	R( 
Me3C_< Me2CHCH2-_( 
(24) 	(25) 	 (26) 	 (27) 
The principle disadvantage of such anhydrides is the presence of two electrophilic 
centres which can (and do) give a mixture of products. By varying the nature of R' it is possible 
to effect the electron density at the carbonyl centre and favour nucleophilic attack at one or the 
other position. Thus trimethylacetic anhydrides (where R=Me 3C) (25) which donate strongly and 
isovaleryl (26) mixed anhydrides, give only traces of the unwanted peptide. This method was 
used successfully in the solution phase synthesis of oxytocin by du Vig neaud et aL5 Replacement 
of the carboxylic acid moiety with half-esters of carbonic acid 62' (27) greatly reduces the 
electrophilicity of the adjacent carbonyl. This is caused by the electron donating effect of the 
neighbouring oxygen 
20 
Two problems associated with the use of mixed anhydrides are the disproportionation to 
symmetrical anhydrides and the possibilty of racemisation. These are minimised by use of short 
activation times at low temperatures. 
A further development has been the replacement of the carboxylate group with a 
phosphonate in a mixed anhydride. These do not seem to undergo attack by the incoming amino 
group in the phosphorus moiety and this is due, in part, to its excellent leaving group properties. 
Many phosphoric and phosphinic acid derivatives have been investigated as coupling reagents 
in peptide synthesis. Recent work within this research group had lead to the development of 
diphenylphosphinic anhydride (28) which can be used to prepare mixed anhydrides (29) as shown 




 . Po 
(28) 








Scheme 12. Preparation of mixed anhydrides from diphenylphosphinic anhydride. 
This brief overview of solid phase peptide synthesis indicates the wide variety of options 
that are available in the nature of the solid support, in coupling methods and in protection strategy. 
By choosing the correct options it is possible to extend peptide synthesis into the successful 
9 '49° synthesis of proteins. 
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1.2 The use of the helix-turn-helix motif for sequence specific DNA 
binding. 
This topic has recently been reviewed in depth by Harrison and Aggarwal: only the 
salient points are presented here. The control of gene expression is of central importance in 
biology. At any given time, each cell uses only a subset of its genes to direct the synthesis of other 
molecules. This process of controlled gene expression is usually regulated at the level of 
transcription and an essential part of this control is the binding of regulatory proteins to the 
recognition sequences of the appropriate genes. The recognition of specific DNA sequences is 
achieved through discrete DNA binding domains which are generally small: in the region of 40 to 
100 amino acid residues. Proteins and peptides of this size are increasingly becoming accessible 
by solid phase synthesis 9 ' 47 and are of a suitable size for 1 H n.m.r. stucturedetermination 65'' 67 . 
1.2.1 Recognition by the helix-turn-helix-motif. 
The recognition of specific DNA sequences by many proteins bearing the helix-turn-helix 
(HTH) motif is now well characterised. Many such proteins exhibit a low affinity binding to non-
operator sequences, but a much higher affinity (roughly 105  fold) affinity for their particular 
operator sequence from the DNA. There are several reasons for this: 
The edges of base pairs in B-DNA project hydrogen bond doners and acceptors into 
the major groove in a sequence specific manner. These provide protein to base pair hydrogen 
bonds that are very important in the sequence specific binding. 
The second HTH helix lies in the major groove of B-DNA and the specificity of the 
interaction between this helix and the DNA has been demonstrated in an experiment which 
swapped the recognition helices of two DNA binding proteins. The DNA binding sequence 
specificity of the two proteins had also been exchanged 69 ' 70 . However, this does not work in every 
case, indicating that other interactions are also important. 
The local conformation of B-DNA shows considerable variability. In addition, many 
helix-turn-helix bearing proteins cause considerable bending of the DNA binding site. It is entirely 
feasible that a protein could 'indirectly' recognise DNA through the variations in the position of the 
phosphate and sugr groups that occur upon binding. 
1.2.2 The helix-turn-helix sequence. 
The helix-turn-helix motif may be described as a sequence of about twenty residue. A 
selection of these is shown in table 2. 
Helix 	
]-
Turn Recoinition Helix 
16 	
35 
X-cro Gln-Thr~Lys-Thr-Ala-Asp-Lys-Leu-Gly-Val-Tyr-Gln-Ser-Ala-Ile-Asn -Lys-Ala-Ile-H is  
33 	
52 
k-Rep Gln -Glu-Ser-Val-Ala-Asp-Lys-Met-Gly-Met-Gly-Gln-Ser-Gly-Val-Gly-Ala-Leu-Phe-A sn  
17 	
36 



























Table 2. Sequences of several helix-turn-helix motifs, compiled from refs. 64,69 and 71. 
The sequences come from phage ?. (dl, rep and cr0); from phage 434 (434 rep and cr0); from 
the E. co/i catabolite gene activator protein (CAP); from the tryptophan operon repressor (tip rep); 
from the lactose operon repressor (lac rep) and from the Antennapedia gene product (Antp) from 
Drosophila.. 
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Residues 1-7 form the first HTH helix and residues 12-20 form the second. Residue 9 is 
usually Gly because of the backbone flexibility required in the bend region. In addition, a number 
of hydrophobic residues at positions 4, 8, 10, 16 and 18 are also conserved. The second helix is 
sometimes refered to as the 'recognition' helix as it is this region which slots into the major groove 
at the operator site, as shown in figure 4. The region of DNA that a protein binds to is called an 



















Figure 4. The binding of phage X cro protein dimer to DNA. Helices 2 and 3 form the helix-
turn-helix motif and helix 3, which fits into the major groove, is often refered to as the recognition 
helix. The Cro protein dimer shows a twofold axis of symmetry which is coincident with an 
imperfect axis of symmetry in the operator site. Adapted from ref.71. 
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1.2.3 Determination of the structure of helix-turn-helix proteins by n.m.r 
The first requirement in determining protein and peptide structures by n.m.r is a 
sequential assignment of all the resonances in the complex 1 H n.m.r. spectrum. With the wide 
range of 1 H homonuclear methods that have been developed it is now possible to obtain this 
information for proteins of up to 100 residues 65 ' 72' 73. Once this hase been achieved, then 
structural constraints, derived principally from 20 nuclear Overhauser enhancement spectros-
copy, are then used to generate a structure using distance geometry calculations and restrained 
molecular dynamics. 
The lac repressor headpiece. 
The lac repressor protein DNA-binding domain (or 'headpiece') is a globular domain of 
51 to 59 amino acid residues from the lac repressor. 1 H n.m.r. has been used to determine the 
conformation of the 51 residue fragment 74 which confirmed the presence of the helix-turn-helix 
motif. Subsequent n.m.r. studies of the 56 residue fragment complexed to a 14 base pair half-
operator site of DNA 75 have provided a low resolution view of the way in which the protein domain 
interacts with DNA. The structureof this domain is shown in figure 5. 
Figure 5. The structure of the lac repressor headpiece. 
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The Antp homeodomain 
A number of Drosophila developmental gene products and mammalian transcription 
factors contain a 60 amino acid residue region called the homeodomain 76 . The homeodomain 
region of the Antennapedia (Antp) gene product from Drosophila, which has 68 residues has been 
studied by 2D n.m.r and a complete sequential assiginment carried out. The use of nOe data 89 
has allowed the determination of the structure, which has been shown to include a helix-turn-helix 
motif very similar to that found in many prokaryotic proteins, despite having substantial 
differences in other regions of the molecule. 
Figure 6. The structure of the Antp homeodomain, maintaining the same orientation of 
the helix-turn-helix motif as used in figure 5. 
1.2.4 The phage ? Cro protein 
The bacteriophage 2 is a virus which infects the bacterium E.coli. One of the proteins 
coded for by its DNA is the Cro protein, which is involved in controlling the molecular switch that 
decides between two developmental pathways for the virus. It can undergo lysogeny, in which 
the quiescent viral DNA is incorporated into (and replicated with) the host cell DNA. Alternatively, 
it can undergo the lytic pathway, in which the virus takes control of the host cells protein synthesis 
and DNA replication machinery in order to produce a large number of viral progeny, until the 
bacterium bursts open. The progeny then spread and infect other bacteria. The molecular biology 
of this switch and its control are complex (but lucidly reviewed in a monograph by Ptashne 69). 
The choice of developmental pathway is determined by the balance of two viral DNA 
binding proteins called the X repressor and X Cro. These both compete for binding sites on a small 
region of the viral DNA called the right operator (0R)  This small but busy region of viral DNA 
(shown in figure 7A) contains two sites to which RNA polymerase can bind, called promoters 
(RM 
and P R)  Transcription from PR  produces the mRNA that codes for Cro protein. Transcription 
along the other strand, in the opposite direction, produces the mRNA that codes for repressor. 
The region also contains three similar (but not identical) regions of DNA which both the 
repressor and Cro protein bind to. They bind to these operator sites (0R 1 ' 0R2 and 03)  with 
differing affinities and the binding of the proteins blocks the promoters so that RNA polymerase 
cannot bind to that promoter. 
In the first case (shown in figure 7B), if the Cro protein has bound to its two preferred 
operator sites, OR 3 and OR2, then only the P RM  promoter is blocked and RNA polymerase only 
has space to bind at the P R  promoter. This leads to the trancription of more Cro mRNA and to 
the transcription of other proteins downstream from Cm which are required for DNA replication 
and other lytic growth functions. 
The other state (shown in figure 7C) occurs when the repressor protein is bound to its two 
preferred sites 0 R 1 and 0R2 In this case, P 1 is blocked, stopping the production of Cro and the 
other lytic proteins, but P RM  is open to allow RNA polymerase to bind to the P flM  promoter and 
hence produce more repressor. However, the binding of RNA polymerase to the P RM  is not very 
strong and interactions with the repressor at 0 2 help the polymerase to bind. This state occurs 
when the virus has incorporated its DNA into the host cell chromosome and is called lysogeny. 
When certain environmental factors endanger a lysogenic bacterial host cell (one which 
is carrying the virus), the bacterium produces a protein called RecA which acts as a protease on 
the repressor. This causes the concentration of the repressor to fall and eventually exposes the 
P promoter. Once Cro production is underway, it binds tightly to 0 R3 and 0R2,  stopping the 







Figure 7. A schematic representation of the molecular switch which controls the 
development of phage X. (A) show the arrangement on the viral DNA of the promoters (R  and 
PAM), to which RNA polymerase (shown as a large oval in 7B and 7C) can bind. It also shows the 
operator sftes (0R1' 0R2  and 0 R 3 , all shaded) to which the repressor and Cro proteins (shown 
as filled circles) can bind. 78 shows the. arrangent during lytic growth and 7C shows the 
arrangment during the lysogenic phase. 
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Cro has only 66 residues with a molecular weight of 7351 Da per monomer and has been 
well characterised8°81.'82 . Cro folds into a single globular domain and the Cro monomers have 
a high affinity for each other and form a stable dimer (figure 4), even at the low concentrations 
typically found in infected cells. It has been crystallised and the structure has been determined. 
This has shown that Cro has a very simple structure: three strands of antiparallel n-sheet 
(residues 2-6, 39-45 and 48-55) and three a-helices (residues 7-14, 15-23 and 27-36). 
1 	 15 
M E Q R I T L K A Y A M R F G 
16 	 30 
Q T K T A K A L G V Y Q S A I 
31 	 45 
N K A I H A G A L I P L T I A 
46 	 60 
A D G S V T A E E V K P F P S 
61 	66 
N K K T T A 
Figure 8. The sequence of phage ?. Cro. 
The Cro structure was used to propose the molecular basis for DNA-protein recogni-
tion85, as shown in figure 3. Acomplex between X cro and a 17 base pairduplex of DNA containing 
the 0R3 sequence was subsequently crystailised and its structure studied. This has revealed 
that although the main substance of the model described above is correct, there are considerable 
changes in the positions of the two subunits of the dimer relative to each other. 
The protein-DNA interactions have also been studied by protection and base substitution 
experiments. These have provided an indication of which specific hydrogen bonds and other 
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Figure 9. The sequence specific interactions of the Cro protein with DNA taken from 
ref. 87. Symbols: j hydrogen bond acceptor, + hydrogen bond donor, o Me 
group of thymine, * N-7 of guanine, •... and " are presumed hydrogen bonds. 
1.2.5 N.m.r. studies of Cro 
Cro had originally been studied by 1 D techniques but these experiments yielded little 
information except that Cro was globular89. The Cro dimer, with a molecular weight of 14.7 kDa, 
was a viable target for sequential assignment. However, the complex of Cro with a synthetic DNA 
sequence from the operator site (with a molecular weight of about 25 kDa) has a long correlation 
time and, accordingly, broad 1 H n.m.r. resonances. 
Cro contains a number of well spaced of aromatic residues (Tyr 10, 26 and 51 and Phe 
14, 41 and 58). By feeding E. Co/i cells overproducing Cro with 3-fluorotyrosine (30) or 3-
fluorophenylalanine (31), Ardnt eta/,96 were able to prepare Cro labelled with a 19 F n.m.r probe 
in these positions. 
OH 
NH2 	CO2 H 	 NH 2 
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They then used this to study the binding of Cro to DNA by following the effect on the 19F 
spectrum of titrating in various quantities of non-specific DNA fragments. The shifting of only one 
tyrosine and none of the phenylalanine resonances may indicate that a single tyrosine is in direct 
contact with the DNA and this consistant with the model proposed by Ohlendorf etal. (shown 
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35 36 	37 	38 	39 	40 
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o.o 	00.5 	 01.0 	 01.5 	 02.0 
pI'l1 
Figure 10. The effect of titrating 19F labelled Cro with non-specific DNA fragments. (A) 
shows the effect on the resonances of the 3-fluorotyrosine substituted Cro and (B) the effect on 
resonances of the 3-fluorophenylalanine substituted Cro. 
A nearly complete sequential assignment of the Cro 1 H n.m.r spectrum has been 
achieved 91 and and the binding of Cro protein to a 17 bp DNA sequence from 0 R3 examined using 
15N labelling experiments 92 . The 15N experiments allowed the C-terminal residues (which are not 
well resolved in the crystal structure) to be observed and they were shown to interact with the 
DNA. 
Metzler and Lu 93 chose to exchange each of the thymines (32) in a 17 base pair duplex 
containing the 03 site with 5-fluorouracil (33). They then measured the solvent accessibility of 
each of these in the presence and absence of Cro. These results indicated that the binding of Cro 










Figure 11. The structures of thymine (32) and 5'-fluorouracil (33). 
1.2.6 Synthetic Studies on Cro 
The first studies on peptides from the Cro protein were carried out before the crystal 
structure was established. Guile et al. 94 prepared a 22 residue fragment from the amino terminus 
of Cro. They also prepared the same sequence except with an additional Cys residue on the 
carboxy terminal. This allowed them to dimerise the peptide and this was found to bind 
preferentially to ? DNA and to polyG. 
Mayer et aL 95  have synthesised a peptide corresponding to the recognition helix 
(residues 26-39) and studied its folding using 10 n.m.r., using hexafluoroisopropanol (HFIP)/ 
water mixtures to induce some secondary structure. They also studied the addition of a synthetic 
DNA duplex to the peptide in HFIP/water (1:4) and showed changes occured in the 10 tH  n.m.r. 
spectrum. Whilst these results are interesting and indicate DNA:peptide interactions are 
occurring, more conclusive evidence would come from a re-examination of the system using 2D 
n.m.r. techniques. 
Recently Sheppard etal. have published96 the results of some extensive studies into the 
synthesis of Cro by fragment condensation methods (figure 12). By using the very acid labile 
linker (34) it was possible to assemble protected peptides and cleave them from the solid support 
with 1% TFA in dichloromethane. As they point out, this was not strictly an orthogonal strategy 
(ci. the fluoride labile linkers of Barany and of Ramage), but by carrying out the cleavage as 
a flow process and neutralising the acid effluent, they were able to practically eliminate the loss 
of But  side chain protecting groups. OMe 
Me} 
HOM 
0"~CO2H Me Me MeO 
So2 
(34) 	 (35) 
32 
1 	 12 
H-Met-Glu-Gln-Arg-Iie-Thr-Leu-Lys-Asp-Tyr-AIa..Met. 
13 	 24 
Arg-Phe-Gly-GTh-Thr-Lys-Thr-Ala-Lys-Asp-Leu-G ly- 
25 	 36 
V a I - Ty r- Gin - S e r - Al a - I I e - A sn - L y s - Al a - lie - H is - Al a - 
37 	 48 
GIy-Arg-LyS-Ile-Phe-Leu-Thr-lie-Asn-AIa-Asp-Gly- 
49 	 60 
Ser-Val-Tyr-Ala-Glu-Glu-Val-Lys- Pro- Phe-Pro-Ser- 
61 	 66 
Asn-Lys-Lys-Thr-Thr-Ala-OH 
Figure 12. The sequence of X Cro, showing the planned (dashed lines) and actual (solid 
lines) protected fragments synthesised for the assembly of Cro. Taken from ref. 96. 
One of the principle problems that they encountered was the insolubility of the fully 
protected peptide fragments that were produced. This remains an obstac& to the preparation of 
extended protein sequences by fragment condensation. Unfortunately, experiments with a 
purified sample of the natural X Cro showed that it was intrinsically unstable to trif luoroacetic acid 
and was substantially degraded after 2 hours of exposure to the acid. The arginine protecting 
groups which had been used, Mtr (35), required protracted treatment with TFA to be completely 




2.1 The preparation of Bnpeoc derivatives 
2.1.1 The design of a novel base labile protecting group 
The base labile 9-fluorenylmethoxycarbonyl protecting group has proved very successful 
in solid phase peptide synthesis' 49 '50 . The concept of a truly orthogonal protecting strategy such 
as the Fmoc/But  system is both intellectually appealing and practically convienient. 
The removal of the Fmoc group is usually achieved with 20% (vlv) piperidine in DM F and 
the initial product, dibenzotulvene, is then trapped as its piperidine adduct (scheme 6, page 11). 
However there are a number of problems associated with the use of Fmoc amino acid derivatives 
in solid phase peptide synthesis. A number of the Fmoc amino acids or their symmetrical 
anhydrides are not soluble in dichloromethane 52 , which is thought to be the best solvent for 
activation50 ' 51 and has been used routinely during solid phase peptide synthesis in the BoclBzl 
strategy. Futhermore, the Fmoc amino acids are between two and five times more expensive as 
their Boc equivalents. 
When considering potential novel protecting groups for solid phase peptide synthesis, 
several important criteria must be considered: 
The protected derivatives must have a good shelf life, preferably at room 
temperature. 
The protecting group must be readily prepared and introduced. 
The deprotection conditions used must be almost quantitative and selective under 
mild conditions. 
The by-products of deprotection should be easily removed. 
The reagent should not be toxic. 
Ramage and Florence 31 chose to develop an alternative to the Fmoc group using the 
following approach. The removal of the bond between the two phenyl rings of Fmoc gives 
diphenylethoxycarbonyl (36). 
O_CO_ 	 O_CO_ 
(36) 
35 
The diphenylethoxycarbonyl group is a very poor n-eliminating group because of the 
reduced acidity of the 0 hydrogen. In order to increase this, the introduction of an electron 
withdrawing nitro group in the para position was considered. 
cJ 02N 	 NO2 
Consideration of the PKa'S  of the compounds shown in figure 13 suggests that, providing 
ease of deprotection is related solely to the acidity of the 0 hydrogen, then the 2,2bis(4'-
nitrophenyl)ethoxycarbonyl protecting group should be labile to weaker bases than is Fmoc, since 
the a leaving group is identical. This protecting group was independently developed, but 
inadequately characterised, by König etaL 97 Five amino acid derivatives were prepared by them, 
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2.1.2 The preparation of 2,2-bis(4'-nitrophenyl)ethoxycarbonyl N-hydroxysuccin- 
imide. 
Florence3' developed two routes to the preparation of the key intermediate, 2,2-bis(41-
nitrophenyl)ethanol (37) and the more viable route is shown in scheme 13. Several modifications 
of this route have been studied. The synthesis of large quantities (1-2 kg) of 2,2-bis(4'-
nitrophenyl)ethoxycarbonyl-N-hydroxysuccinimide (BnpeocONSu) (38) was carried out using 
this route, without modification but substantially scaled up. 
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Scheme 13. The synthesis of Bnpeoc-ONSu (38). 
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The first step in the route involves the reaction of styrene oxide (39) with phenyl 
magnesium bromide. The Grignard reagent can attack eitherof the carbon atoms in the epoxide 
ring leading to two possible products (scheme.14). 
/\ 
PhMgBr -  OH + C~'CH—CI-12  
0 	
\/ 
(39) 	 (41) (40) 
Scheme 14. The reaction of phenylmagnesium bromide and styrene oxide. 
Kharash and Clapp showed.that the product of attack at the least hindered site, 1,2 
diphenylethanol (40), was obtained when a solution of the Grignard reagent was added to the 
styrene oxide solution. However, addition of the styrene oxide to the Grignard gave the 2,2-
diphenylethanol (41). If this were the result of similar kinetics for attack at both carbon atoms 
(which might be predicted for a highly reactive nucleophile) then a 1:1 mixture of the isomers would 
be expected. However, yields in excess of 70% of the 2,2 diphenylethanol can be obtained. A 
possible explanation of this is the binding of a Lewis acid to the oxygen atom as shown in figure 
14. 
O"CH—CH 2  
Figure 14. The binding of a Lewis acid (L)to styrene oxide. 
The polarisation of the carbon oxygen bond leads to a partial carbocation that can be 
stabilised by the phenyl group. Therefore the carbon atom proximal to the phenyl group is more 
susceptible to attack, by suitable nucleophiles, leading in our case to the required alcohol (41). 
Grignard reagents are known to be equilibrium mixtures as shown in scheme 15 and II seems 
likely that the magnesium ions are acting as the Lewis acid in this case. 
2 PhMgBr 	 PhMg + MgBr2 
Scheme 15. 
In practice, the yield of the reaction proved variable (between 40 and 60%) and the lower 
yields were experienced in the lamer scale (3.0 mol) preparations. Attempts to distil (under high 
vacuum) more of the product from the liquors that remained after crystallisation gave no more of 
the required product. The main fraction isolated from this distillation was biphenyl. 
The 2,2-diphenylethanol (41) was readily acetylated, in quantitative yield, with acetic 
anhydride in the presence of a catalytic quantity of conc. sulphuric acid. In an attempt to reduce 
the number of steps in the synthesis, a direct route of synthesising 2,2-diphenylethylacetate (42) 
was attempted as shown in scheme 16. Instead of isolating the product of the reaction between 
the Grignard reagent.and styrene oxide, a slight molar excess of acetyl chloride was added to the 
magnesium 2,2-diphenylethoxide (43) solution. Unfortunately a mixture of products, including 
both the 2,2-diphenylethanol (41) and its acetate (43) were obtained. Given the excellent yield of 
the acid catalysed acetylation reaction, this work was not carried any further. 










Scheme 16. The direct synthesis of 2,2-diphenylethylacetate (42). 
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The nitration of the 2,2-diphenylethylacetate (42) using a mixture of conc. sulphuric and 
conc. nitric acid proceeded with an acceptable yield of 58%. Thetemperature of the reaction 
mixture was found to be critical: if the temperature fell below -5°C the rate of reaction became 
slow, but if allowed above 0°C the yield was reduced, probably through side reactions such as 
nitration at the ortho position. The reaction was exothermic and careful precautions (such an ice/ 
salt bath and vigorous stirring) had to be taken to ensure that the heat generated was quickly 
dissipated and the temperature thereby kept constant. 
The acid catalysed methanolysis of the 2,2-b/s(4'-nitrophenyl)ethylacetate (44) to the 
2,2-bis(4'-nitrophenyl)ethanol (37) proceeded very cleanly and was essentially quantitative. 
Recently Grae has investigated an alternative route to 2,2-bis(4'-nitrophenyl)ethanol 
shown in scheme 17. Nitration of the diphenylmethane (45) proceeded in acceptable yield (50-
60%) and the anion (46) was readily formed, as evidenced by the intense blue colour which 
appeared immediately on adding the base. Unfortunately, the expected reaction of this anion with 
formaldehyde did not occur because of the highly delocalised nature of the anion (46), which 

























Scheme 17. An alternative route to 2,2-bis(4-nitrophenyl)ethanol (37). 
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Treatment of the 2,2-bis(4'-nitrophenyl)ethanol (37) with phosgene (used as a toluene 
solution) and N-methylmorpholine afforded 2,2-bis(4'-nitrophenyl)ethylchloroformate (47), which 
could be isolated as a white crystalline solid (with identical physical characterisitics to those 
decribed by Florence31 ). However, the chloroformate (47) was usually not isolated. The N-
methylmorpholine hydrochloride salt which had precipitated out during the reaction was removed 
by filtration and then the crude chioroformate solution was converted directly to the N-
hydroxysuccinimidyl carbonate (38) by the addition of a further equivalent each of N-methylmor-
pholine and N-hydroxysuccinimide. The solution was again filtered to remove the precipitated N-
methylmorpholine hydrochloride salt. Subsequent removal of the solvent in vacua gave a yellow 
solid, which after washing with cold actetone and petrol, gave Bnpeoc-ONSu as a white solid in 
82% yield. The overall yield from styrene oxide was 26%. 
2.1.3 The preparation of Bnpeoc protected amino acids. 
Many of the simpler NaBnpeoc  protected amino acid derivatives, which do not require 
side chain protection, have been synthesised and described by Florence 31 . In addition, Bnpeoc-
Ser(Bu)-OH and Bnpeoc-Thr(Bu t)-OH have been prepared by Gray. Many of the expensive 
side chain protected derivatives were synthesised from the parent amino acid. These were 
prepared by literature methods (or adaptations of them) and are described and referenced in 




Z-Asn-OH 	 Z-Asn-OBzl 
65-70°C 	 81% 
i) H3O 
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Scheme 18. The preparation of H-Asp(OBut)-OH 
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Z-CI 	 Mbh-OH/H 
H-Gin-OH 	 Z-GIn-OH 	 Z-GIn(Mbh)-QH 




Scheme 19. The preparation of H-GIn(Mbh)-OH 
i)Boc20/TEA 	 I) H30 
Z-Lys-OH 	 Z-Lys(Boc)-OH,Dcha 	 p 
ii)Dcha 	 87% 	 ii) H2/Pd-C 
H-Lys(Boc)-OH 
74% 
Scheme 20. The preparation of H-Lys(Boc)-OH 
Z-Ci 	 Mbh-OH/W 
H-Asn-OH 	-'- Z-Asn-OH 	 '- Z-Asn(Mbh)-OH 
	




Scheme 21. The preparation of H-Asn(Mbh)-OH 
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Z-Cl 	 i)BzlBr/Dcha 
H-Glu-OH 	• Z-Glu-OH 	 Z-GIu(OH,Dcha)-QBzl 
79% ii)Dcha 	 66% 
H30 	 H2IPd-C 
ZGlu(OBut)OBzl 	• HGIu(OBut)OH 
isobutylene/H 	 47% 	 88% 
Scheme 22. The preparation of H-Glu(OBu t)-OH 
The Bnpeoc amino acids were all prepared by an adaptation of the method of Rich. The 
amino acid or side chain protected derivative was dissolved or suspended in a mixture of dioxan 
and water (1:1) and 1.5 equivs. of triethylamine was added. The solid Bnpeoc-ONSu (38) was 
then added and the reaction followed by tIc until it had reached completion (4-16 hours). The 
Bnpeoc protected amino acid was isolated by acidifying the medium and extracting the derivative 
into an organic phase. The amino acid derivatives that readily crystallised were purified by 
recrystallisation, but the derivatives which proved difficult to crystallise were purified by conver-
sion to the cyclohexylamine (Cha) or dicyclohexylamine (Dcha) salts. These salts were 
recrystallised and were then converted back to the pure free acids in near quantitative yields by 
partitioning the salt between an organic solvent and aqueous potassium hydrogen sulphate 
solution (2.0 M). The free acids were obtained either as a foam or as a orecioitate from 
chloroform/petroleum ether. This process was used to prepare a suitable quantity of each amino 
acid derivative for solid phase peptide synthesis (usually between 5 and 30 grams). Some of the 









Bnpeoc-Ala-OH 147-148 +0.8 (1.0 DMF) 90 A 
Bnpeoc-Arg(Pmc)-OH 120-140 +16 (1.0 CHCI3) B, C, 0 
Bnpeoc-Arg(Pmc)-OH ,Cha 136-137 79 B 
Bnpeoc-Asn-OH 180-182 +0.5(1.0 DMF) 83 A, G 
Bnpeoc-Asn(Mbh)-OH 114-115 -2.1 (1.0 DMF) 87 
Bnpeoc-Asp(OBu')-OH 75-79 C, D 
Bnpeoc-Asp(OBu)-OH,Dcha 160-164 +1 7.4 (1.0 CHCI3) 69 
Bnpeoc-Cys(SBu t)-OH,Cha 175-178 75 H 
Bnpeoc-Gln-OH 189-190 -3.9 (1.0 DMF) 94 A 
Bnpeoc-Gln(Mbh)-OH 97-107 +5.8 (1.0 DMF) 62 
Bnpeoc-GIu(OBu t)-OH A, D 
Bnpeoc-Glu(OBu t)-OH,Dcha 129-132 +5.3 (1.0 DMF) 88 A 
Bnpeoc-Gly-OH 156-159 90 A 
Bnpeoc-His(Trt)-OH 134-138 +4.4 (1.0 DMF) 85 
Bnpeoc-IIe-OH A, C, E 
Bnpeoc-lle-OH, Dcha 158-159 +7.7 (1.0 DMF) 92 A 
Bnpeoc-Leu-OH 68-70 +4.9 (1.0 DMF) 92 A 
Bnpeoc-Lys(Boc)-OH 76-79 +7.6 (1.0 CHCI3 ) C, D 
Bnpeoc-Lys(Boc)-OH,Dcha 146-149 +2.9 (1.0 DMF) 93 
Bnpeoc-Met-OH +8.1 (1.0 DMF) E 
Bnpeoc-Met-OH,Dcha 186-1 89 81 A 
Bnpeoc-Phe-OH 77-78 -16.5 (1.0 DMF) 93 A 
Bnpeoc-Pro-OH 74-79 -18.7 (1.0 DMF) 91 A,G 
Bnpeoc-Ser(Bu t)-OH +13.7 (1.OMeOH) C, E, F 
Bnpeoc-Ser(Bu t)-OH,Cha 182-185 +11.0 (1.0 DMF) 93 
Bnpeoc-Thr(Bu t)-OH +9.7 (1.0 MeOH) C,E,F 
Bnpeoc-Thr(Bu t)-OH,Cha 153-156 +11.0 (1.0 DMF) 55 
Bnpeoc-Trp-OH 94-97 -24.0 (1.0 DMF) 91 A,G 
Bnpeoc-Tyr(Bu t)-OH 73-76 -20.0 (0.8 OMF) 75 
Bnpeoc-Val-OH 142-145 +7.5 (1.0 DMF) 89 A,G 
Table 3. Bnpeoc amino acid derivatives. 
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Notes 
The optical rotations were all recorded at room temperature (approx.25°C). c and the 
solvent are given in brackets. 
Reference 31 
Reference 36 
For those derivatives isolated as their Dcha and Cha salts, the yield for the 
conversion to the free amino acid is nearly quantitative. 
0: Isolated as a powder. When analysis indicated these were pure and free of 
solvents the optical rotation and m.p. were recorded. 
Isolated as a foam. 	 - 
Reference 33 
Reference 100 
H. Reference 101 
2.1.4 The deprotection of Bnpeoc derivatives 
Experiments carried out by Florence 31 have indicated that the Bnpeoc group is very 
stable to acids and no modification is detected in TFA over 24 hours or in 3N HCI in methanol over 
18 hours. It is not cleaved by pyridine or 2,6-lutidine. Not surprisingly, catalytic hydrogenation (for 
two hours) gave two major products (in a mixture with the starting material) which, after separation 
by silica chromatography, were shown to be the products of reduction of one or both nitro groups: 
the 2(4-nitrophenyl)-2(4-aminophenyl)ethyl and the 2, 2-bis(4'-aminophenyl)ethyl derivatives. 
G rae has undertaken a comprehensive study of the stability of Fmoc- and Bnpeoc-Ser-
OBzl in several solvents (DMF, DMA and NMP). The results have suggested that both of the 
protecting groups are cleaved by basic impurities present in these solvents. The rate of cleavage 
is dependent on the purity of the solvent, but the Bripeoc derivative is more sensitive. However, 
the Bnpeoc amino acids, in which the carboxylic acid functionality is unprotected, are not affected 
by these solvents over 44 hours. This is probably because the carboxylic acid is protonating any 
basic impurities in the solvents. 
C ONOD 
DBU (48) 	 DBN (49) 
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The Bnpeoc group may be cleaved by the addition of strong tertiary bases such as 
diazabicyclo-(5.4.0)-undec-7-ene (DBU) (48) and diazabicyclo-(4.3.0)-non-5-ene (DBN) (49) 
with rapid n-elimination of 1,1 -bis(4'nitrophenyl)ethene (50) (scheme 23). A transient blue colour 
is observed in the reaction vessel, characteristic of anions of the type (51) which fades as the 
reaction reaches completion. This process occurs in the presence of equimolar quantities of 
base, even it these are buffered with acetic acid 31 . 













RNHO 	 RNH'O 
(51) 	 Jr 
ON 	 NO 
RNH2 + c02 - RNH 0 
H 
(50) 
Scheme 23. The cleavage of the Bnpeoc group by DON or DBU. 
The Fmoc group is usually cleaved during solid phase peptide synthesis using a solution 
of 20% piperidine (vlv) in DMF and results in the formation of the piperidine adduct. The 









Scheme 24. The reaction of 1,1 -bis(4-nitrophenyl)ethene (50) with piperidine to give the 
piperidine adduct (52). 
Addition of piperidine to a solution of the olefin in DMF results in a strong blue colour 
(indicating the formation of an anion) which fades as this reaction reaches completion. It remains 
unclear whether the quaternary ammonium centre loses its proton before or after the delocalised 
carbanion gains one (and both routes are shown in scheme 25). UV spectroscopic studies of the 
conversion of the olefin (X 304 nm) to the piperidine adduct (A 270 nm) have indicated 33  
that the addition reaction occurs very quickly (essentially complete within three minutes) at the 
concentrations typically used during automated solid phase peptide synthesis. 
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2.2 Solid phase peptide synthesis 
In the this section and in the experimental chapter, the yield quoted is calculated from the 
resin loading. This may not truly represent the success of the synthesis because during 
chromatographic separations the fractions were selected on a basis of purity and not yield. The 
objective of the work described in this section was to use the Bnpeoc protected amino acids in 
conjunction with a variety of other reagents to prepare peptides from two proteins, Ubiquitin and 
phageACro. 
2.2.1 Monitoring the progress of peptide synthesis. 
The most frequent point of failure in solid phase peptide synthesis is the coupling reaction 
and any indication of where a poor coupling occurs can be used to optimise the synthesis. An on-
line direct method of measuring of the coupling reaction would be ideal but until recently 102 ' 103 
it has proved elusive. However the piperidine adduct of dibenzofulvene is an excellent chromo-
phore and its release from the peptidyl resin during the N-terminal deprotection step can be 
monitored at 314 nm and the automated synthesiser has been adapted to measure this 104 . During 
each cycle, after removing the Fmoc group with 20% piperidine in DMF, the effluent from the 
reaction vessel is passed through a UV cell, monitoring at3l 5 nm and the absorbance displayed 
on a chart recorder (figure 15). 
Because the deprotection reaction is usually very efficient (with respect to the coupling 
reaction) the integrated peak area can give a rough indication (+1- 5%) of the efficiency of the 
previous coupling reaction. This system has been further adapted to allow the monitoring of 
syntheses carried out using the Bnpeoc protected amino acid derivatives by changing the 




1st 	2nd 	3rd 	4th 	Time - 
F- 
F- - 
Figure 15. The cleavage of the Fmoc group, monitored at 315 nm. During each cycle the 
peptidyl resin is washed and vortexed fourtimes with 20%(v/v) piperidine in DMF(for3, 3,3 and 
1 minutes respectively). After each wash (labelled 1St to 4th) the effluent from the reaction vessel 
is passed through a UV absorbance detector. 
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2.2.2 Preparation of the loaded resins. 
Target peptides with C-terminal amides were synthesised using the dibenzosuberanyl 
derivative (5)27  (figure 1, page 8) as a linker. This is cleaved under conditions compatible with the 
final deprotection used in the Fmoc/But  strategy. For preparation of peptides with C-terminal 
carboxylic acids, the first residue was coupled to the p-alkoxybenzylalcohol resin outwith the 
automated peptide synthesiser. Two methods of coupling were used. In the first case, Fmoc-Gly-
OH was coupled successfully (35%) using DIG to prepare the symmetrical anhydride in DMF. 
DMAP was also required (0.2 equivs) and a final loading of 0.32 mmol/g was obtained. However 
this method required the use of a six fold excess of the amino acid derivative and such large 
excesses are routinely required to form the benzyl ester. 
The second amino acid derivative to be loaded was Bnpeoc-Gln(Mbh)-OH, which had to 
be synthesised from its parent amino acid. Such a wasteful method of loading was unacceptable 
and an alternative method was used. The diphenylphosphinic mixed anhydride (scheme 12, page 
20) was prepared from diphenylphosphinic anhydride (prepared by the method of Gray 33) and 
then coupled to the resin in the presence of DMAP (0.1 mmol) in an excellent yield (92 0%). 
Comparing the loading of Fmoc-Gty-OH and Bnpeoc-Gln(Mbh)-OH, it is clear that, 
despite the bulky side chain protecting group and the use of fewer equivalents of amino acid, the 
diphenylphosphinic anhydride activation resulted in a more efficient coupling reaction. 
It is desirable that only the most unhindered fraction of all the available functionalised 
sites within the resin matrix are acylated, so that there is a large volume for the peptide chain to 
grow into, particularly during the synthesis of longer sequences. However, this incomplete 
acylation of the resin leaves available the remaining sites for acylation during subsequent 
couplings. In order to stop this occuring the loaded resins were each capped using benzoyl 
chloride, by the method described by Wang21. 
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2.2.3 Peptldes from Ubiquitin. 
The small protein called Ubiquitin has 76 amino acids (figure 16) and has been the target 
of a substantial synthetic effort °5 A laie number of peptides from this protein have been 
synthesised, with the objective of understanding how each of the structural elements 
contribute to the stable tertiary structure. Some of the peptides were synthesised as C-terminal 
amides and with the N-terminus acetylated, since the charges of the terminal carboxylate and 
ammonium ions (which are not present in the natural protein sequence) might distort the structure 




Lys-Thr-Ile-Thr-Leu-G1u-Va 1-Giu-P ro-Ser- 
21 








I le-Gln-Lys-Glu-Ser-Thr-Leu-His-Leu-Va 1- 
71 
Leu-Arg-Leu-Arg-Gly-Gly-OH 
Figure 16. The sequence of Ubiquitin. 
Three small -tum regions from the molecule (residues 6-12, 44-49 and 50-56) and a 
region spanning two of the turns (residues 36-53) provided an excellent opportunity to test both 
the Bnpeoc group and the diphenyiphosphinic anhydride coupling methods. 
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Ubiquifin residues (36-53). (53) 
This synthesis was carried out to test the efficiency of the diphenylphosphinic anhydride 
coupling reagent in conjunction with the Fmoc/But protection strategy 10" 1 . The Fmoc amino 
acids were double coupled using two equivalents of the mixed anhydride. The diphenyiphosphinic 
anhydride was loaded on the synthesiser using the small cartridges that are used to deliver the 
Fmoc amino acid derivatives. Glycine was only single coupled with four equivalents of the mixed 
anhydride. After cleavage and deprotection the crude peptide (figure 17) was purified by 
preparative h.p.l.c. in a yield of 45%. -- -- - 
------- ___j ) __.__------------------------------------___________l_____________ 
±-± 
-: -------------------------------- -------------- 
- 
- --- ---------- --------------- 
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-. --------- ------- -----
----------- ---- 
-- 
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Figure 17. H.p.l.c. trace of the crude product from the synthesis of Ubiquitin residues (36- 
53). 
Initial n.m.r. studies of the peptide in 90% H 20/1 0% D 2  0 resulted in the identification of 
all the amino acid spin systems. However, these studies also indicated that the peptide was 
probably not adopting a stable secondary structure and the n.m.r. studies were stopped at.this 
point. 
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Ubiquitin residues (44-49) (54) 
H-ile-Phe-Ala-Gly-Lys-Gln-OH 
The peptide was synthesised using diphenyiphosphinic anhydnde as the coupling 
reagent and Bnpeoc protected amino acid derivatives.. Each residue was double coupled with 
two equivalents of mixed anhydride (except Gly which was single coupled with tour equivalents). 
DMF was used as the solvent throughout the synthesis. The UV monitoring of the synthesis 
indicated that the last coupling reaction (lie onto Phe) had not gone to completion. The poor 
coupling of 13-branched amino acid derivatives has been previously observed 9 and so this might 
have been predicted. Furthermore, after cleavage and deprotection, a major and minor product 
were observed by h.p.l.c. (figure 18). These were each purified and both mass spectrometry and 
amino acid analysis indicated that the material from the minor peak was the capped (acetylated) 
derivative produced after the failure of the last coupling reaction. 
Figure 18. Analytical h.p.l.c. of crude hexapeptide (54). 
53 
Ubiquitin residues (6-12) amide (55)andAcetyl Ubiquitin (6-12) amide. (56) 
(Ac- or H-)-Lys-Thr-Leu-Thr-Gly-Lys-Thr-N H 2 
The synthesis was carried out on a 0.5 mmol scale using Bnpeoc amino acids and single 
two equivalent couplings with the BOP reagent 57,58 in dichloromethane. The synthesis proceeded 
with high efficiency (as judged by the UV monitoring of deprotection) and once the peptide had 
been assembled the last Bnpeoc group was removed (with 20% piperidine in DM F) and half the 
resin was reacted with acetic anhydride. The acetylated peptide was then cleaved from the resin 
and the side chains deprotected, purified by reverse phase h.p.I.c. and isolated in 50% yield. The 
remaining resin was cleaved and deprotected, then purified in a similar mannerto give the purified 
peptide in 53% yield. Dunng this synthesis the Bnpeoc amino acids (1.0 mmol) all dissolved 
readily in 0CM (4 ml). 
Ubiquitin residues (50-56) amide (57)andAcetyl Ubiquitin (50-56) amide (58). 
(Ac- or H-) Leu-Glu-Asp-Gly-Arg-Thr-Leu-N H 2 
The synthesis was carried out on a 0.5 mmol scale, double coupling with dipheny-
Iphosphinic anhydride activation to give two equivalents of the mixed anhydride, except for 
glycine which was coupled only once with four equivalents of mixed anhydride. After the peptide 
had been assembled and the last Bnpeoc group had been removed, the peptide was divided into 
two porlions. One half was deprotected and cleaved from the resin directly and the other half was 
acetylated after which it was cleaved and deprotected. 
The crude heptapeptide (57) (isolated in 47% yield) was purified by reverse phase h.p.l.c. 
and obtained pure in the disappointing yield of 14%. This separation proved difficult because of 
the hydrophilic nature of the peptide. The acetylated derivative (58) (figure 19) was isolated in a 
similar manner, but with a slightly better yield of 22%. An impurity was also isolated in 8.5% yield 
and comparison of the mass spectra, amino acid analyses and 1 H n.m.r. indicated that the 
impurity was a des-Leu derivative. There are two Leu residues, but providing that the capping 
reaction used after each coupling is effective, this would seem to indicate that the coupling of the 
final Leu onto the preceeding Glu was incomplete. 
M. 
Figure 19. Analytical h.p.l.c. of crude heptapeptide (58). (A) is the.required peptide and 
(B) is the impurity which lacks a Leu residue. 
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2.2.4 Synthesis of Peptides from the phage ? Cro protein. 
The peptides which were selected from the Cro protein were all taken from the DNA 
binding region (the Cro sequence is shown in figure 12, page 32). In future n.m.r. studies it may 
be possible to study the interaction (if any) of these peptides with synthetic DNA operator site 
sequences. 
The recognition helix Ac- Cro residues (25-40)-NH2 (59). 
Ac-Val-Tyr-Gln-Ser-Ala-lle-Asn-Lys-Ala-His-Ala-Gly-Arg-Lys-Ile-N H 2 
This peptide sequence contains the recognition helix of the Cro protein which binds to the 
major groove of the DNA operator site 69. The three residue C-terminal extension,-Arg-Lys-lle-, 
is thought to provide counterions to the negatively charged phosphate groups in the DNA sugar-
phosphate backbone. 
The synthesis was carried out manually in a 'bubbler' reaction vessel 106 , on a 0.5 mmol 
scale with TBTU activation 59 ' 107. Single two equivalent couplings with Bnpeoc amino acids were 
monitored bythe Kaiserlesi' °8 and recoupled using BOP activation when required. The sidechain 
functionality of the GIn was protected by Mbh 41 . 
The initial cleavage and deprotection of an aliquot the assembled peptide gave a mixture 
of products. The reaction was repeated and a small sample was withdrawn every half hour and 
subjected to analytical h.p.l.c. After two hours (figure 24A) a complex mixture was observed, but 
after a further hour (figure 2413) a major peak developed. Mass spectrometry of the material 
showed two major peaks near the molecular ion (m/z=1810), at m/z=1907 (MH+97) which 
remains unidentified, and at m/z=2037 (MW+227). This second peak is consistent with 
incomplete removal or scavenging of the Mbh protecting group. These ions were both reduced 
in intensity in the mass spectrum of material isolated after 3 hours of cleavage and deprotection. 
A larger batch of the matenal was then cleaved and deprotected and the crude peptide purified 
by cation exchange chromatography. The fractions containing the required material were pooled 
and further purified by reverse phase h.p.l.c. A poor yield (8.6%) was obtained as expected and 
reflects the problems of deprotection and the need fortwo chromatographic separations. The use 
of alternative carbocation scavengers (such a 1 ,2-ethanedithiol or phenol) might have reduced 
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Figure 20. Analytical h.p.l.c. traces of crude (59) after 2 hours (A) and after 3 hours (B) 
(A) 
(B) 
deavage and deprotection. 
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Attempted synthesis of the Cro protein. 
The synthesis of the entire Cro sequence (66 residues, figure 12, page 32) was likely to 
be a demanding synthetic problem. The natural Cro protein was thought to be unstable to 
extended treatment with TFA 109 although nothing was known about the modification or 
degradation that occured. The problems experienced by Atherton et aL were due, in a large 
part, to the conditions required (6 or more hours in TFA and scavangers) toremove the arginine 
protecting group then in use, Mtr (35). 
OMe 




Figure 21. The Mtr (35) and Pmc (60) arginine protecting groups. 
The 2,2,5,7,8 pentamethylchroman-6-sulphonyl (Pmc) protecting group (figure 21) has 
subseqUently been developed and has been shown to be cleaved at a rate (in under two hours) 
compatible with the Fmoc/But  strategy37. This protecting group was thought more likely to allow 
the successful deprotection of the peptide, without an unacceptable degree of modification. 
Experience obtained during the synthesis of Ubiquitin 105 had shown that the UV 
monitoring of the synthesis was useful in optimising the conditions used during the synthesis, 
particularly of longer (over approx. 25 residues) sequences. 
To be set against these improvments in synthetic methods, the natural Cro protein is not 
commercially available, so it could not be used as a marker during chromatographic separations. 
Consequently even if thesynthesis proceeded smoothly, the methods used to characterise the 






The synthesis was carried out on the 'Sasrin' linker (61), a linker which is very acid labile 
because of the methoxy group which is ortho to the benzyl ester. This allows the peptide to be 
cleaved from the resin under very mild conditions (1% TFA in 0CM). The synthesis was carried 
out on a 0.25 mmol scale with Fmoc protected amino acid derivatives. Residues 6610 29 were 
triple coupled (two equivalents) with TBTU activation 107. However, the solubility of this reagent 
proved unreliable (varying from batch to batch) and this may have been responsible for several 
poor couplings. For the final part of the synthesis (residues 2810 1) each amino acid was double 
coupled, firstly as the symmetrical anhydride (formed with DIG, two equivalents) and then with 
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Figure 22. Plot of the UV monitoring peak area against cycle number. 
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The integral obtained from the UV monitonng of the synthesis was plotted against cycle 
number (figure 22). There were several incomplete couplings in thesynthesis. The region 
between 8 and 16 residues has been reported as consistently difficult 9 and on cycle 10 (marked 
in figure 22, Pro coupled onto Phe) a substantial drop in the peak area occured. The recovery 
after this drop is perhaps even more worrying, since it suggests that the capping reaction did not 
block all the remaining amine sites left after the incomplete coupling. The deletion peptides from 
such a coupling failure are likely to be very similar to, and therefore difficult to separate from, the 
complete sequence. 
At cycle 22 (Asn coupled onto Ala) a particularly poor coupling was observed. The reason 
for this remains unclear; it could be a result of the TBTU not dissolving or because of secondary 
structure formation in the growing peptide chain. The final peak area after the assembly had been 
completed was about 16% of the initial value. Although this is an inefficient assembly of the Cro 
sequence, it does serve to illustrate the usefulness of the monitoring method for indicating 
problems during a synthesis. Any subsequent syntheses can be optimised, with extended 
coupling times and recoupling of the residues that have been shown to be slow to couple. A slight - 
change of solvent (such as a mixture of dioxan and DMF) and/or the adding of 'chaotropic' 
reagents 11° to disrupt secondary structure in the peptidyl resin are all possible methods for 
improving these couplings. 
Since the Cro protein is unstable to TFA 109, only a small aliquot of the resin was cleaved 
and deprotected; samples were withdrawn from the mixture every 20 minutes and the crude 
peptide was rapidly isolated from each of these and then analysed by h.p.l.c. The optimal 
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Figure 23. The analytical reverse phase h.p.l.c. of: (A) a sample of crude Cro protein after 
1 hour 40 minutes; (B) the first eluted fraction from gel filtration chromatography; (C) the second 
eluted fraction from gel filtation chromatography. 
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Experiments were also carried out in which the balance of scavengers in the reaction 
mixture was varied. The ideal mixture was found to be: TFA/EDT/anisole/water in the ratio 
10:1:1:1. A larger batch of resin was then cleaved from the resin and deprotected. The crude 
peptide was isolated by precipitation with diethylether. If the peptide was dried in this form and 
stored, it subsequently proved less soluble in aqueous media. It was therefore advantagous to 
redissolve the peptide in aqueous buffer immediately after its isolation. It was then applied to a 
Sephadex G50 column which allowed the separation of two major peptidyl fractions [figure 23, 
and (C)I. Massspectrometry and amino acid analysis indicated that the second eluted fraction 
was the capped peptide produced by the incomplete coupling of cycle 22, identified with the 
UV monitoring method. 
The other fraction was analysed by SDS polyacrylamide gel eletrophoresis. The major 
component had a molecular weight of approx. 6.2 kDa (as measured against standards of known 
molecular weight), which was compatible with the Cro protein (7.3 kDa). DNA binding proteins 
often have phosphate binding sites and a number have been purified by using phosphocellu lose 
affinity chromatography. Phosphocellulose has been used for the purification of the Cro protein 
from natural sources81 , but gave very poor seperation of impurites from the synthetic Cro. Cation 
exchange chromatography using CM-Sephadex proved far more successful (figure 24) and the 
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Figure 24. The major fraction after (A) cation exchange chromatography and (B) after 
reverse phase h.p.l.c. 
An aliquot of this material was further purified by microbore h.p.ic. to a single peak and 
the sequence of the first 10 residues was confirmed by automated Edman degradation 111 . 
Sequencing was stopped at this point until further characterisation of the purified material had 
been carried out. The remainder of the material was purified by preparative reverse phase h.p.l.c. 
and studied by 252Cf plasma desorbtion mass spectrometry 112 . The mass spectrum showed a 
broad peak centred at 7366 (+1- 7) Da (Cr0 requires 7351 Da). This suggested that the sample 
contained a number of similar pepides and subsequent analytical h.p.l.c. indicated that the 
material had indeed undergone some modification since it had been purified (a period of about 
four weeks). This might be due to residual TFA in the h.p.l.c. buffers, or to the lyophilisation of 
the peptide from these buffers. 
At this pointthe work was stopped (as the peptidyl resin from this synthesis had all been 
used). However, several useful points have been demonstrated: 
The chemical synthesis of small proteins can be followed and subsequently optimised 
using the UV monitoring of the deprotection reaction. 
A numberof different methods of characterisation are useful in determining the nature 
and purity of an isolated peptide: this is particularly true when a sample of the natural material is 
not available. 
A number of purification methods must be applied sequentially to obtain the peptide 
in a pure state. 
Great care must be excercised when handling synthetic proteins. In particular, the use 
of lyophilisation to concentrate the protein or the use of preparative h.p.l.c. may have been the 
cause of some of the problems encountered in this purification. 
Although the pure material isolated could not be well characterised it seems likely from 
the amino acid analysis, sequencing data and mass spectrometry, that it was either the Cro 
protein or a slightly modified analogue of it. In either case, these results suggest that after 
optimising the synthesis and improving the purification procedures, the synthesis of the Cro 
protein should be possible. 
Synthesis of Acetyl Cro residues (15-37) amide (62) 
Ac-Gly-Gln-Thr-Lys-Thr-Ala-Lys-Asp-Leu-GIy-Val-Tyr-Gln-Ser-Ala-lle-Asn-Lys-Ala-
lle-His-Ala-Gly-N H 2 
This peptide forms the helix-turn-helix motif of the Cro protein. As well as being of interest 
for structural studies, it was chosen as a test peptide for the comparison of synthetic methods. 
The same batch of resin was used for three syntheses, carried out using the methods shown in 
table 4. 
Synthesis Protection Activation UV monitor Yield (%) 
Fmoc HOBtJDIC 314 nm 61 
ii Fmoc TBTU 314 nm 31 
iii Bnpeoc HOBt/DIC 405 nm 37 
Table 4. Yield is estimated from the integrated peak areas observed using the UV 
monitoring of deprotection. The estimated error in these values is +1- 5% 
The comparison of the TBTU and HOBt/DIC activation methods, with single five 
equivalent couplings, shows that the DIC/HOBt was clearly the better method. When a 
companson is made using the Bnpeoc and the Fmoc groups, the Fmoc synthesis gives a clearly 
better yield. These results are confirmed by a comparison of the crude peptides by analytical 
h.p.l.c. (not shown). The Bnpeoc synthesis gave a large number of minor products, which 
accounts for the poor overall yield. It may be that the Bnpeoc group is slightly, (but in this case, 
critically) more sensitive to the basic impurities present in the DMF. Certainly, the syntheses of 
small Ubiquitin fragments (55) and (56) using Bnpeoc amino acids, which were carried out in 
DCM, gave crude products which contained far fewer impurities. 
Considering the excellent solubility properties of the Bnpeoc amino acid derivatives in 
less polar solvents, such as DCM and dioxan, it would be interesting to carry out a comparative 
synthesis in one of these solvents. Since HOSt is not very soluble in these solvents, an alternative 
coupling reagent (for example HBTU or BOP) could be used. A direct comparison with Fmoc 
under these conditions would unfortunately be difficult because of the poor solubility of some 
Fmoc derivatives in these solvents. 
The crude peptide from synthesis (i) was purified by h.p.l.c. in 38% yield. This material 
was used to study the secondary structure of the peptide by 1 H n.m.r. From the crystal structure 
of the Cro protein it is known that the first helix provides hydrophobic interactions to the recognition 
helix. In the case of the isolated peptide, such hydrophobic interactions might be mutually 
stabilising for both helices. In order to study the structure of a peptide or protein by n.m.r. a 
complete sequential assignment must be carried out. The two dimensional homonuclear 
techniques were used for this, in a strategy adapted 113 from that developed by Wüthrich72. 
Correlated Spectroscopy (COSY) 
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Nuclear Overhauser Enhancement Spectroscopy (NOESY) 
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Figure 25. The interactions that can be observed in a glutamine residue by three two 
dimensional 1 H n.m.r experiments. 
In a COSY spectrum, the observed cross peaks are usually for two (geminal) or three 
bond couplings. Such spectra cannot show couplings across the peptide bond, but instead show 
the isolated spin system of each amino acid. The TOCSY spectrum has similar constraints, 
except that it can show longer distance couplings provided that the intermediate carbon or 
nitrogen atoms are bonded to a hydrogen atom. 
NOESY spectra show through space interactions and so this technique can show the 
interaction of the aCH of residue I and the nearby aNH of residue i+1, across the intervening 
peptide bond. This therefore allows the spin systems of the amino acids which have been 
identified by COSY and TOCSYto be linked together and hence sequentially assigned. 
The NOESY spectrum can also provide structural constraints, which in conjunction with 
restrained molecular dynamics can produce a high resolution structure of the protein or peptide. 
Initial studies of the peptide in aqueous solution suggested that the peptide had no stable 
secondary structure. The use of methanol (which is known to promote secondary structure 
formation) produced spectra which indicated the formation of secondary structure and therefore 
a more detailed analysis was carried out. 
The spin systems of each residue were usually identified from the TOCSY spectrum and 
then cross referenced to the COSY spectrum. The TOCSY spectrum was particularly useful in 
assigning the y,  8 and E protons in extended amino acid side chains. However, the side chains 
of the lIe, Val and Leu residues were more easily assigned from the less crowded COSY 
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Figure 26. A region of the TOCSY spectrum of (62) showing the couplings to amide 
protons. 
The sequential assignment was carried out using the same region as shown in figure 27 
but from the NOESY spectrum. Initially pairs of residues showing clear cross peaks were linked, 
and then the sequence extended along the chain in both directions. In regions where the aCH 
to NH1 1 cross peaks overlapped othercross peaks, other interactions, such as J3CHto NH 1 cross 
peak was used. These cross peaks were also used to check other assignments wherever 
possible. This provided a complete sequential assignment, a part of which is shown in figure 27. 
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Figure 27. Part of the sequential assignment of peptide (62) using a region of the NOESY 
spectrum. 
The last requirements were the assignment of the side chain amides of GIn 16 and 27 
(via the NOESY crosspeak of the)CH 2and the 5NH2), the side chain amide of Asn 31 (via a similar 
NOESY cross peak between the PCH 2 and the )NH 2) and the C-terminal amide (assigned by 
elimination of all the other peaks). The 3,5-H and 2,6-H aromatic resonances of Tyr were 
differentiated by the NOESY cross peak from the Tyr 1CH 2 to the 2 and 6-H. The 2-H of His 
showed a NOESY cross peak to the 3CH2 and a TOCSY cross peak to the 4-H. 
We 




Figure 28. NOESY cross peaks indicative of an a-helix forthe peptide (62). Cross peaks 
between sequential NH's (NN 111 ), between the aCH of residue i and either the NH of residue 1+3 
(aNIk3) or jCH of residue i+3 (a1 k3)  are shown. They were classified by eye as strong, medium 
or weak. The proposed a-helix is boxed. 
Once the sequential assignment had been carried out, some of the cross peaks to amide 
resonances were identified. Each type of secondary structure has a characteristic pattern of 
associated NOESYcross peaks. The observed pattern (figure 28) is consistant with the formation 
of an a-helix between residues 27 and 36, which is required for the recognition helix of the Cro 
protein. Many of the peaks for residues 15 to 25 overlap in the NOESY spectrum and it is difficult 
to determine the secondary structure for this region. The residues that would be expected to form 
the 'turn' show a few weak NOESY cross peaks but no clear structure has yet been determined. 
The one dimensional 1 H n.m.r. spectrum was also studied in mixtures of water and 
methanol (a region of these spectra are shown in figure 29). Of particular interest is they methyl 
resonances of Val 25 (marked with the arrow in figure 29). The position in water was 
unambiguously assigned from a TOCSY experiment in water. The substantial shift of this 
resonance (from 0.85 to 1.14) on changing the solvent from water to methanol could be caused 
by a change in the relative position of the Val 4.1e to the aromatic ring of Tyr 26 (with its associated 
ring current). Alternatively, the formation of the a-helix would result in the generation of a helix 
dipole with the Val positioned at the positive end. Interestingly, the peak shape of the Val 25 Me 
resonance becomes broader in both 10 and 30% H 20 in MeOH. It is sharp in both methanol and 
water and in all the other mixtures. 
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Figure 29. The 1 D 1 H n.m.r. spectrum of peptide (62) in different proportions of water and 
CD3OH. 
Whilst these results are interesting, there are many more n.m.r. experiments that could 
be carried out. Of particular interest would be studies of peptide (62) bound to a synthetic DNA 
operator site, since this would provide a relatively simple model of the binding of the helix-turn- 
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helix motif to DNA, which might be of use in predicting the properties of proteins other than Cro 





All amino acids used were purchased from the SAS group of companies; protected 
derivatives were purchased from Bachem or Novabiochem and were used as supplied. Melting 
points were taken in open capillanes on an electrically heated Buchi 510 melting point apparatus, 
oron microscope slides on an electrically heated Reichart 7905 melting point apparatus and are 
uncorrected. Thin layer chromatography (tic) was carried out on plastic sheets coated with silica 
gel 60GF-254 (Merck 5735) in the following systems: 
1/5, ethyl acetate/light petroleum (b.p. 40-60 °C) 
1/4, ethyl acetate/light petroleum (b.p. 40-60 °C) 
30/70, ethyl acetate/light petroleum (b.p. 40-60 °C) 
40/60, ethyl acetate/light petroleum (b.p. 40-60 °C) 
18/2/1, chloroform/methanol/acetic acid. 
16/4/1, chloroform/methanol/acetic acid. 
19/1, ethyl acetate/acetic acid 
2111/1, ethyl acetate/n-butanol/acetic acid/water 
3/1/1, n-butanol/acetic acid/water 
1/1/1, cyclohexane/ethyl acetate/methanol 
Visualisation of the compounds was achieved by using the following methods as 
appropriate: iodine vapour, ultra-violet absorbtion at 254 nm, Mary's reagent [4,4'-
bis(dimethylamino)diphenylcarbinol], acidified potassium permanganate and ninhydrin. H.p.l.c 
was carried out using Applied Biosystems equipment (2 x 1406A solvent delivery systems, a 
1 480A injector mixer and a 1 783A detector controller), or its equivalent. The gradients that were 
used are summarised in table 5. The sample was injected, followed by the isocratic and then the 









(1) 	(2) 	(Mm) 
Column Size 
mm 
A 1.0 10 	4 10 	90 	25 ABIRP18 220x4.6 
B 3.6 30 	5 30 	50 	20 ABIRP18 lOOxlO 
C 1.0 0 	4 0 	100 	30 ABI RP18 100x4.6 
D 4.0 5 	4 5 	15 	15 ABIRP18 250x10 
E 1.0 5 	4 5 	25 	20 ABI RP18 220 x 4.6 
F 5.0 5 	4 5 	35 	20 ABIRP18 250x10 
G 1.0 5 	4 5 	35 	20 ABI RP1 8 220 x 4.6 
H 1.0 5 	4 5 	40 	30 Capital ODS-SB5 250 x 10 
3.0 5 	4 5 	15 	15 ABIRP8 250x10 
J 4.0 10 	4 10 	50 	20 ABIRP18 250x10 
K 3.5 5 	5 5 	40 	30 ABIRP18 250x10 
L 1.0 5 	5 5 	50 	20 Capital ODS-SB5 250 x 4.5 
M 1.0 5 	4 5 	20 	20 ABI RP8 220 x 4.6 
Table 5. The conditions used for reverse phase h.p.l.c. Buffer A was 0.1% TFA in water. 
Buffer B was 0.1% TFA in acetonitrile. (1) gives the percentage of A at the start of the gradient 
and (2) gives the percentage of A at the end of the gradient. 
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Amino acid analyses were carried out on either a LKB 4150 alpha or a LKB 4151 A alpha 
plus amino acid analyser, following hydrolysis in constant boiling hydrochloric acid at 110°C for 
an appropriate length of time (24-72 hours). Infra-red spectra were recorded on a Perkin Elmer 
781 spectrophotometer in the solvent stated or as a nujol mull, using polystyrene (1603 cm -1 ) 
as a standard. Ultra-violet spectra were recorded on a Varian Gary 210 spectrophotometer. 
Wavelengths are quoted in nanometers and extinction coefficients are quoted in dm 3 mor 1 
cm 1 . Optical rotations were measured using an Optical Activity AA1 000 polarimeter. Optical 
rotation measurements of known compounds were performed under identical conditions (con-
centration and solvent) to those stated in the literature, unless otherwise noted. Mass spectra 
(F.A.B.) were measured on a Kratos MS 50TC spectrometer. Proton nuclear magnetic resonance 
spectra were recorded on Bruker WP80 (80MHz), WP200 (200MHz) or WH360 (360MHz) 
instruments using tetramethylsilane as the standard (=0.00), or on the Varian VXR600S 
(600MHz). Spectra recorded on this instrument were referenced either to H 2  0 (at 4.8 p.p.m. at 
250C) orto CD2HOH (at 3.315 p.p.m. in CD3OH). Elemental analyses were carried out on a Carlo 
Erba model 1106 elemental analyser. The following solvents were distilled before use and were 
dried using the reagents given in parentheses: chloroform (phosphorus pentoxide), dichlorom-
ethane (calcium hydride), diethyl ether (sodium wire), ethyl acetate, tetrahydrofuran (benzophe-
none/sodium), ethanol (magnesium ethoxide). Light petroleum (b.p. 40-60°C) refers to the 
fraction which boils between 40 0 and 60°C. 
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3.2 Preparation of side chain protected amino acid derivatives. 
HIRT-1 F1 a 
The title compound was prepared by the method of Boissonas etaL11 '. Benzylchloroformate (137 
ml, 0.97 mol) was added to a cooled (ice bath) stirred solution of asparagine monohydrate (132 
g, 0.8 mol) dissolved in NaHCO3 (1.0 M, 1.5 I) over a period of two hours. This was allowed to 
warm to room temperature and stirred for 16 hours. The pH of the reaction mixture was tested 
(pH 7-8). The solution was then extracted with diethyl ether (2 x 500 ml) to remove excess 
benzylchloroformate, then adjusted to pH 3 with conc. hydrochloric acid (approx. 100 ml). The 
solution was left to stand at 4°C for 24 hours to allow the product to crystallise, after which it was 
collected by filtration, washed with water (2 x 300 ml) and dried in vacuo at40°C to give the title 
compound (175.5 g, 82%) as a white solid: m.p. 157-159°C (lit., 114 163°C); [a] +87° (c 1.0, 
glacial acetic acid) (lit., 4 +9.61). 
Na..Benzyloxycarbonylasparag i ne  benzyl ester 
Z-Asn-OBzl 
The title compound was prepared by the general method of Netkens and Nirvard 56 . 
Z-Asri-OH (70.0 g, 0.26 mol) was dissolved in DMF (350 ml) and dicyclohexylamine (54 ml, 0.27 
mol) was added. The stirred mixtu rewas warmed to 65-70°C and benzylbromide (31 ml, 0.26 mol) 
was added. After 30 min the dicyclohexylammonium bromide which had precipitated was 
removed by filtration and the mixture poured onto crushed ice (1.2 I). The white precipitate which 
formed was filtered and dissolved in ethyl acetate. The solution was washed with NaHCO 3(aq.) 
(800 ml) and water (3 x 500 ml) and then dried (MgSO 4). The solvent was reduced in vacuoto 
a volume of about 200 ml and the product was left to crystallise for 24 hours. The solution was 
then filtered and the title compound dried in vacuo: (64 g, 81%); m.p. 127-128°C (14., 115 131-
1320C); [a]D  -14.1 0 (c2.5 in DMF) (Iit., 5 -12.90). 
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The title compound was prepared by the general method of Nelkens and Nirvard 116 . 
Z-Asn-OBzl (40.0 g, 112 mmol) was dissolved in glacial acetic acid (550 ml) and stirred. 
HO3SONO (21.4 g, 168 mmol) was then added in small portions (3-4 g) at intervals of five mm. 
The solution was maintained at less than 25°C throughout, then stirred for one hour. Ethyl acetate 
(200 ml) was then added and the solution was boiled for three mm. The solvent was reduced in 
vacuoto a small volume and then the residue was poured into water (1200 ml). This suspension 
was extracted with ethyl acetate (3 x 300 ml) and the combined organic phase washed with water 
(3 x 500 ml) and brine (500 ml), then dried (MgSO 4) and the solvent reduced in vacuo to a small 
volume (about 100 ml). Cyclohexylamine (13.75 ml, 1.0 equivs.) was then added and the title 
compound (35.24 g, 69%) precipitated out by the addition of diethyl ether in two crops as a white 
solid: m.p. 126-129°C; tIc -E, R 1 0.6 
N -Benzyloxycathonyl aspartic acidjbenzyl ester 
Z-Asp-OBzl 
Z-Asp(OH ,Cha)-OBzl (30 g, 66 mmol) was suspended in KHSO 4 (2.0 M. 500 ml) and ethyl acetate 
(500 ml). After stirring for two hours, the ethyl acetate was separated and the aqueous phase was 
extracted with ethyl acetate (2 x 250 ml). The combined organic phase was then washed with 
water (2 x 500 ml) and with brine (1 x 300 ml). The ethyl acetate was then removed in vacuo and 
the residual oil was crystallised from diethyl ether/light petroleum (b.p. 40-60°C) to give the title 
compound(21.2 g, 90%) as a white solid: m.p. 82-83°C (lit., 116 84-85.50C), tic -E, RO.6; 6H(80 
MHz; CDCI3) 2.96 (2H, t, JCH 2), 4.67 (1 H, m, aCH), 5.10, 5.15 (2 x 2H, 2 x s, Bzi and Z CH 2's), 
5.90 (1 H, d, aNH), 7.29, 7.31 (2 x 5H, Z and Bzl Ar-H), 9.86 (1 H, br, PCO 2H). 
The title compound was prepared by an adaptation of the method of Schwyzer and Dietrich 7 . 
Z-Asp-OBzl (30 g, 84 mmol) was dissolved in dichloromethane (300 ml) and the solution was 
poured into a thick walled flask, then cooled in an acetone/dry ice bath. Condensed isobutylene 
77 
(100 ml), conc. sulphuric acid (0.5 ml) and CuCl (50 mg) were then added. The vessel was closed 
securely and left to react for 14 days at room temperature, with occasional turning to mix the 
reagents. The flask was then cooled in an acetone/dry ice bath,opened and allowed to warm to 
room temperature, with evaporation of the excess isobutylene. The solution was then washed 
with Na2CO3 (1.0 M, 3 x 100 ml) and then the organic layer was concentrated in vacuo. Ethyl 
acetate (500 ml) was then added and the organic layer washed with water (3 x 400 ml) and brine 
(1 x 250 ml), dried (MgSO 4) and the solvent removed in vacuoto leave an oil (23.2 g, 67%). A 
small sample was crystallised from ethyl acetate/light petroleum (b.p. 40-60 °C) as a solid: m.p. 
• 42-45°C (lit., 117 45747.50C); 8 H(80  MHz; CDCI3) 1 .36(9H, s, 3 x CH 3 , 
Bu),  2.82 (21-1, t, Asp 3CH2), 
4.62 (1 H, m, Asp aCH), 5.11 and 5.16 (2 x 2H, 2 x s, Z, Bzl CH 2), 5:71 (1 H, d, Asp aNH), 7.31, 
7.32 (2 x 5H, 2 x s, Bzl, Z Ar-H's). 
I!L1.1:11ie!s1: 
Z-Asp(OBu t)OBzl (22.35 g, 52 mmol) was dissolved in methanol (100 ml), cooled to 0 °C and 
stirred under an atmosphere of nitrogen. Palladium on charcoal catalyst (2.2 g, 10% w/w) was 
then added in small portions. The mixture was then stirred under an atmosphere of hydrogen for 
24 hours. The solution was then filtered through a pad of pre-washed 'Celite' to remove the 
catalyst and concentrated in vacuo to a volume of 50 ml. The addition of diethyl ether (100 ml) 
produced a white gel which was filtered and dried in vacuo at 40°C to give the title compound(7.63 
g, 77%) as a white powder: m.p. 183-184°C (lit., 189-1900C); [aJD  +9.9° ( C 1.02 in 90%AcOH) 
(lit., 1 14 +850) 
The title compound was prepared by the method of Kbnig and Geiger41 . Z-Asn-OH (30 g, 113 
mmol) and bis(4-methoxyphenyl)methanol (27.5 g, 113 mmol) were suspended in glacial acetic 
acid (350 ml) and conc. sulphuric acid (3 drops) was added. The mixture was stirred for 24 hours, 
then poured into water (1000 ml) and extracted with ethyl acetate (4 x 400 ml). The combined 
organic phase was washed with water (3 x 1000 ml) and brine (1 x 500 ml), then dried (MgSO 4 ) 
and the solvent removed in vacuoto leave a white solid. Recrystallisation from tetrahydrofuran/ 
light petroleum (b.p. 40-60°C) gave the title compound(50.1 g, 90%) as a white solid: m.p. 166-
171°C (lit., 41 176-1800C). 
H-Asn(Mbh)-OH 
The title compound was prepared by the method of K&nig and Geiger. Z-Asn(Mbh)-OH (10.0 
g, 20.4 mmol) was suspended in glacial acetic acid (100 ml) and stirred under an atmosphere of 
nitrogen. 10% Palladium on charcoal catalyst (5% w/w) was added in small portions. The 
suspension was then stirred under an atmosphere of hydrogen for 24 hours. The catalyst was 
then removed by filtering the solution through a pad of prewashed 'Celite'. The solvent was then 
removed in vacuoand the product triturated with sodium acetate (1.0 M, 100 ml). The solidified 
product was filtered, washed with water and dried to give a pale grey solid (5.5g, 75%); m.p. 215-
2200C (lit., 41 215-2170C);tic-E, RO.23, -J, R 1 0.47. 
N-Benzyloxycarbonylglutamine 
Z-Gln-OH 
The title compoundwas prepared by the method of Boissonas etaL11 '. Glutamine (50 g, 0.34 mol) 
was dissolved in NaHCO 3 (1.0 M, 1.01) and cooled to 0°C with stirring. Benzylchloroformate (50 
ml, 0.35 mol) was added dropwise over 30 min and the solution was then allowed to warm to room 
temperature. The solution was stirred for 24 hours, then extracted with diethyl ether (2 x 500 ml) 
and acidfied to pH 1.0 with conc. hydrochloric acid. The resulting precipitate was filtered, washed 
with cold water, dried in vacuo at 40°C for 24 hours to give the title compound (66.9 g, 70%) as 
a white solid which was used without further purification: m.p. 127-128°C (Iit., 4 135°C). 
The title compoundwas prepared by the method of Knig and Geiger 41 . Z-Gln-OH (56 g, 0.2 mol) 
was suspended in glacial acetic acid (500 ml) and solid bis(4-methoxyphenyl)methanol (49 g, 0.2 
mol) was added. Conc. sulphuric acid (0.5 ml) was then added dropwise. The mixture was stirred 
for 20 hours and then poured into water (1.5 I) and extracted with ethyl acetate (3 x 500 ml). The 
combined organic phase was washed with water (3 x 700 ml) and brine (1 x 500 ml), dried 
(NJa2SQ4) and the solvent removed in vacuo. The residue, a colourless oil, was then crystallised 
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from TH F/light petroleum (b.p. 40-60 °C) to give the title compound(48.9 g, 48%) as a white solid: 
m.p. 111-115°C (lit., 41 117-1200C); [a]D +2 .40 ( C 2.0 in DMF) (lit., 41 +2.430); 6H[80  MHz; 
(CD3)2S0] 2.51 (21-1, m, GIn 3CH 2), 2.60 (2H, m, Gin 'yCH 2), 3.69, 3.71 (2 x 3H, 2 x s, 2 x OCH3 , 
Mbh), 4.30 (1H, m, GIn aCH), 5.03 (21-1, s, ZCH 2), 6.0 (1H, d, Gin (xNH), 6.75-8.25 (81-1, m, Mbh 
Ar-H), 7.33 (51-1, s, Z Ar-H), 8.60 (1 H, d, Gin 'yNH). 
N -[bis(4-M ethoxyphenyl)methyl]glutamine 
H.Gln(Mbh)-OH 
The title compound was prepared by the method of König and Geiger 41 . Z-Gln(Mbh)-OH (25 g, 
49.4 mmol) was dissolved in a mixture of glacial acetic acid (150 ml) and methanol (150 ml) and 
the solution was cooled to 0°C. 10% Palladium on charcoal catalyst (1.25 g, 5% w/w) was added 
under an atmosphere of nitrogen. The mixture was then stirred for 16 hours under an atmosphere 
of hydrogen at room temperature. The catalyst was then removed by filtration through a pad of 
prewashed 'Celite'. Diethyl ether (200 ml) was added to the solution to precipitate the title 
compound (11.9 g, 65%) as a grey solid: m.p. 200-202°C (lit., 41 205-206°C); [a]0 +9.2° (c 2.0 
in glacial acetic acid) (lit.,' 41 +7.50 ). 
UulH1fTI 
The title compound was prepared by the method of Goldschmidt and Jutz 8  Glutamic acid (73.4 
g, 0.5 mol) was dissolved in a mixture of NaHCO 3 (1.0 M, 500 ml) and NaOH (4.0 M, 200 ml) and 
the stirred solution was cooled to -5 °C. Benzylchloroformate (125 ml, 150.4 g, 0.88 mol) was 
added dropwise over 30 min and the solution was then allowed to warm to room temperature and 
stirred for 16 hours. The solution was washed with diethyl ether (2 x 200 ml) and adjusted to pH 
2 with conc. hydrochloricacid. The precipitate which formed was filtered, washed well with water 
and dried in vacuo at 40°C for 24 hours., The crude product was recrystallised from ethyl acetate/ 
light petroleum (b.p. 40-60°C) to give the title compound (110.3 g, 79%) as a white solid: m.p. 
117-120°C (lit., 118 120-121 0C); tIc -J, R 0.75. 
If1i'2! 
Lclmr. 	 -- 
The title compound was prepared by the method of Nefkens and Nirvard 116 Z-Glu-OH (80.2 g, 
285 mmol) was dissolved in DMF (100 ml) and the solution stirred at -5°C. Triethylamine (42 ml, 
302 mmol) was added, followed by benzylbromide (40 ml, 336 mmol) and the solution was allowed 
to warm to room temperature. The mixture was stirred for 16 hours, then poured into water (500 
ml) and the oil extracted with ethyl acetate (3 x 400 ml). The combined organic phase was washed 
with water (3 x 500 ml) and brine (500 ml), then dried (MgSO 4) and concentrated in vacuo to a 
volume of about 500 ml. This solution was then cooled to 0°C and dicyclohexylamine (63.5 ml, 
318 mmol) was added. Portions of diethyl ether were added to keep the suspension mobile while 
the product precipitated. The product was filtered, washed in diethyl ether (2 x 100 ml) and 
recrystallised from ethanol to afford the title compound(1 04 g, 66%) as a white solid: m.p. 160-
1630C (litJ 6  162-1640C). 
Benzyl-N -(benzyloxycarbonyl)glutamate 
Z-Glu-OBzl 
Z-Glu(OH, Dcha)-OBzl (60 g, 108.5 mmol) was suspended in citric acid (aq.) (20% w/v, 1000 ml) 
and extracted with ethyl acetate (3 x 400 ml). The combined organic phase was washed with 
water (3 x 300 ml) and brine (500 ml), dried (MgSO 4) and the solvent removed in vacuo to give 
a yellow oil. The title compound (32.39,81%) was crystallised from ethyl acetate/light petroleum 
(b.p. 40-60°C) as a white solid: m.p. 95-97°C (lit., 9 m.p. 96.5-98.51C); [a]022 -11.7 (C 3.15 in 
AcOH)(lit., 9 -9.9°); 5H(80  MHz; CDCI3) 1.87-2.20 (21-1, m, Glu 1CH 2), 2.2-2.5 (21-1, m, 'CH 2), 4.43 
(1 H, m, Glu uCH), 5.08, 5.10 (2 x 2H, 2 x s, Z and Bzl CH 2's), 5.53 (1 H, d, Glu aNH), 7.31 and 
7.32 (2 x 5H, 2 x s, Z and Bzl Ar-H), 9.10(1H, br, Glu CO 2H). 
r4c1j[TJ(.1:!l1I.1:U 
The title compoundwas prepared by the method of Morley1 19•  Z-Glu-OBzl (30.0 g, 81 mmol) was 
dissolved in dichloromethane (200 ml) and the solution poured into a thick walled flask and cooled 
in a dry ice/acetone bath. Condensed isobutylene (100 ml) was then added, followed by conc. 
sulphuric acid (0.5 ml) and CuCl (50 mg). The vessel was closed and set aside for two weeks. 
The thick walled flask was then cooled in a dry ice/acetone bath, opened and allowed to warm 
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to room temperature, with evaporation of the excess isobutylene. The organic layer was then 
washed with Na2CO3 (1.0 M, 100 ml x 3) and the solvent removed in vacuo. The residual oil was 
then redissolved in ethyl acetate (500 ml), washed with water (3 x 500 ml) and brine (1 x 500 ml) 
and dried (Na2SO4) and the solvent removed in vacuo. The resultant oil solidified upon trituration 
with diethyl ether/light petroleum (b.p. 40-60°C) (200 ml, 2:1). This solid was then recrystallised 
from ethyl acetate/light petroleum (b.p. 40-60°C) to give the title compound (16.9 g, 47%) as a 
white solid: m.p. 46-48°C (lit., 119 49-51.50C), tIc -K, Rf 0.8. 
Glutamic acid 'y-tert.butyl ester 
H-Glu(OBut)-OH 
Z-Glu(OBut)-OBzl (16.1 9,38.8 mmol) was dissolved in DMF (100 ml) and cooled to 0 °C. 10% 
Palladium on charcoal catalyst (1.5 g, 10% wlw) was added in small portions under an 
atmosphere of nitrogen. The mixture was then stirred under an atmosphere of hydrogen for 72 
hours. The catalyst was then removed by filtration through a pad of pre-washed 'Celite' and the 
filtrate was concentrated to 15 ml in vacuo. The addition of diethyl ether (100 ml) precipitated the 
title compound (6.93 g, 88%) as a white solid: m.p. 180-181°C (lit., 119190-1900C). 
To a stirred solution of Z-Lys-0H 121 (28 g, 100 mmol) in water (100 ml) at 0 °C was added solid 
NaHCO3 (12.5 g, 1.5 equivs.). A solution of di-tert.-butyldicarbonate (26 g, 1.2 equivs.) in dioxane 
(150 ml) was then added dropwise over 10 min and the solution was diluted with dioxan (60 ml) 
and water (60 ml). The solution was then stirred at room temperature for 16 hours. The resulting 
solution was then diluted with water (400 ml) and acidified to pH 3 with KHSO 4 (2.0 M) and 
extracted with diethyl ether (3 x 600 ml). The combined organic phase was washed with water 
(3 x 700 ml) and brine (1 x 700 ml) and dried (MgSO 4). The solvent was removed in vacuo and 
the residual oil was dissolved in ethyl acetate (300 ml). Dicyclohexylamine (21.9 ml, 1.0 equivs.) 
was added dropwise over 20 min and the precipitate which formed was filtered, washed with ethyl 
acetate and dried in vacuo to leave the title compound(46.1 g, 87%) as a white solid: m.p. 155-
1560C (lit., 122156-1570C); [a]D  +7.1 0 (c 1.0 in EtOH) (lit., 1 +7.820);8 H  (80 MHz; CDCI3) 0.9-
2.1 (35H, br m, 3 x CH 3, But,  lOx CH2, Dcha, Lys P ,y,CH2), 2.8-3.1 (4H, m, 2 x CH, Dcha, Lys 
eCH 2), 4.0(1 H, q, Lys aCH), 4.62 (1H, br, NH, Dcha), 5.05 (2H, s, ZCH 2), 5.71 (1H, d, Lys aNH), 
7.29 (5H, s, Z Ar-H), 7.25-8.6 (1H, br, Lys CO2H). 
H-Lys(Boc)-OH 
The title compound was prepared by the method of Scott et aL Z-Lys(Boc)-OH,Dcha (9.07 g, 
16.1 mmol) was partitioned between diethyl ether (400 ml) and KHSO 4 (2.0 M, 400 ml). The 
organic phase was separated and then washed with KHSO 4 (2.0 M, 2 x 100 ml), dried (MgSO 4) 
and the solvent removed in vacuo leaving a sticky foam. 1 H n.m. rwas used to confirm the removal 
of all of the Dcha and the foam was then dissolved in MeOH (250 ml) and water (50 ml) and cooled 
to 0°C. 10% Palladium on charcoal catalyst (10% w/w) was added under an atmosphere of 
nitrogen and the suspension was then stirred under an atmosphere of hydrogen for three days. 
The resulting suspension was diluted with water (600 ml) and filtered through a pad of prewashed 
'Celite' to remove the catalyst. The solvents were then removed in vacuo to leave a white solid 
which was dried in vacuo at 40°C for 24 hours (6.679, 74%); m.p. 259-260°C (dec.) (lit., 124 237-
255°C); [a]0 +7.2° (c 1.0 in 2N NH 4OH) [lit., 124 [a]0 +4.40 (C 0.88 in 2N NH4OH)J. 
EAR 
3.3 The preparation of 2,2-bis(4'-nitrophenyl)ethyl N-succinimidyl carbonate 125 
This compound was prepared by the method of Kharash and Clapp. 
A single crystal of iodine was added to a suspension of magnesium (7.92 g, 0.33 mol) in dry diethyl 
ether (300 ml) under an atmosphere of argon, then bromobenzene (53.4 g, 0.34 mol) was added 
dropwise at a rate sufficient to maintain the reaction at reflux. When the addition was complete 
the mixture was heated under ref lux for 30 min with stirring to produce the Grignard reagent, 
phenyl magnesium bromide. 
The stirred Grignard reagent was then cooled to between 0 and 5°C in an ice bath and a solution 
of styrene oxide (37.2 g, 0.31 mol) in dry diethyl ether (150 ml) was added dropwise over 30 mm. 
The solution was stirred for a further 30 min after which the solution was poured onto a mixture 
of sulphuric acid (2.0 M, 300 ml) and crushed ice (300 ml). The organic phase was separated and 
the aqueous phase extracted with diethyl ether (2 x 300 ml). The combined organic phase was 
washed with sodium bicarbonate solution (2.0 M, 2 x 500 ml), water (3 x 500 ml) and brine (1 x 
500m1), then dried (MgSO 4) and the solvent removed in vacuo. The title compound was then 
crystallised from light petroleum (b.p. 40-60°C) as a white solid (114.85g, 58%): m.p. 60-61°C 
(lit., 56°C); (Found: C, 84.8; H, 7.1. CaIc. for C 14H 140: C, 84.8; H, 7.1%); tIc -A, R f 0.61. 
2,2-Diphenylethanol (41), (5.0 g, 25 mmol) was added in small portions as a solid to acetic 
anhydride (2.57 g, 25 mmol) and then sulphuric acid (98%, 1 drop) was added and the mixture 
was stirred. The solid dissolved and the solution became warm. After 30 min the products were 
poured onto crushed ice (150 ml) and then extracted with ethyl acetate (2 x 100 ml). The combined 
organic phase was washed with sodium bicarbonate solution (2.0 M; 2 x 100 ml), water (2 x 100 
ml) and brine (1 x 100 ml), then dried (MgSO 4) and the solvent removed in vacuo to afford the 
title compound as a yellow solid; recrystallised from diethyl ether (5.19 g, 85%): m.p. 54-55°C 
(lit., 31 m.p. 54-550C); tIc -B, RO.3l. 
2.2-bis(4-Nitrophenyl)ethyl acetate (44) 
A mixture of sulphuric (98%; 70 ml) and nitric (63%: 70 ml) acids were cooled, with vigorous 
stirring, to between -5 and 0°C in an ice/salt bath. 2,2-diphenylethyl acetate (54g. 0.164 mol) was 
added in small portions to the mixture, over a period atone and a half hours, whilst the temperature 
was carefully maintained between -5 and 0 °C by periodic additions of salt to the ice/salt bath. The 
mixture was then stirred for a further two hours and then poured onto crushed ice (500 ml) and 
extracted with ethyl acetate (3 x 400 ml). The combined organic phase was washed with sodium 
bicarbonate solution (2.0 M) until the pH of the aqueous layer was neutral. The organic phase was 
then washed with water (3 x 500 ml) and brine (1 x 500 ml) and dried (MgSO 4). The ethyl acetate 
was removed in vacuo, leaving a yellow oil which was crystallised from diethyl ether to afford the 
title compound (36.39g. 49.1%) as a pale yellow solid: m.p. 1101110C  (lit., 31 107-1080C); (Found 
C, 58.0; H, 4.2; N, 8.4; CaIc. for C 16H 14N206 : C, 58.2; H, 4.4; N, 8.4%); tIc -C, R 0.31. 
2.2-bis(4-Nitrophenyl)ethanol (37) 
2,2-bis(4-Nitrophenyl)ethyl acetate (141 .3, 0.43 mol) was dissolved in methanol (500 ml) and 
conc. hydrochloric acid (16.9 ml) was added dropwise. The mixture was then heated under ref lux 
for five hours. The mixture was then poured onto crushed ice (500 ml) and the solid product was 
extracted into ethyl acetate (250 ml). The organic phase was separated and the aqueous phase 
extracted with ethyl acetate (2 x 250 ml). The combined organic phase was then washed with 
water (2 x 500 ml) and brine (1 x 500 ml), dried (MgSO 4) and the solvent removed in vacuo. The 
product was crystallised from chloroform/diethyl ether to afford the title compound (122.05 g, 
99%) as a white solid: m.p. 104-105°C (lit., 31 109-110°C); (Found C, 58.4; H, 4.2; N, 9.7. CaIc. 
for C 14H 1205N2: C, 58.5; H, 4.2; N, 9.7%); tIc -D, R f  0.25 
2. 2-bis(4-Nitrophenyl)ethyl N-succinimidyl carbonate (31) 
2,2-bis(4-Nitrophenyl)ethanol (64.77g, 0.225 mol) was dissolved in dichloromethane (800 ml) 
and a solution of phosgene in toluene (1.93 M, 176 ml, 1.5 equivs.) was added. N-methylmor-
pholine (25 ml) was added dropwise to this mixture over a period atone hour, with stirring, under 
an atmosphere of dry nitrogen and then the N-methylmorpholine hydrochloride salt which had 
precipitated was removed by filtration. The solvents were removed in vacuo and the residue was 
redissolved in dry 1,4 dioxan (300 ml). The solution was stirred under an atmosphere of dry 
85 
nitrogen and N-hydroxysuccinimide (29.35 g, 0.255 mol, 1.13 equivs.) was added in small 
portions. To this mixture was added N-methylmorpholine (25 ml); more hydrochloride salt was 
then observed to precipitate. The solution was stirred for 16 hours and then the N-methylmor-
pholine hydrochloride.was removed by filtration and the dioxan removed in vacuo, to leave a pale 
yellow crystalline solid which was recrystallised from acetone/light petroleum (b.p. 40-60°C) to 
afford the title compound (79.15 g, 82%) as a white solid: m.p. 183-186°C (lit., 31 173-174°C); 
(Found: C, 53.4; H, 3.5; N, 9.85. CaIc. for C 19H 15N309 : C, 53.3; H, 3.5; N, 9.8%); tIc -E, R 1 0.65. 
W. 
3.4 Preparation of Na12,2bis  (4'-nitrophenyl)ethoxycarbonyl] amino acid derivatives. 
Two routes were used for the preparation of the Bnpeoc amino acid derivatives: 
Route 1: is an adaptation of the general method of Shute and Rich and was used to prepare 
compounds which could be readily crystallised. Bnpeoc-Tyr(Bu t)-OH is given in full as an 
example. 
Route 2: was used for the Bnpeoc derivatives which could not be readily crystallised, in which 
case they were isolated as their crystalline Cha or Dcha salts. The free acid was then liberated 
to give a foam or an amorphous powder. Bnpeoc-Lys(Boc)-OH and its Dcha salt are given in lull 
as examples. 
If-[2 . 2-bis(4' -Nitrophenyl)ethoxycarbonylj - (O-tetbutyl) -L-tyrosine 
Bnpeoc-Tyr( B Ut)OH 
The title compound was obtained by route 1 as follows: a solution of triethylamine (0.42 ml, 3 
mmol, 1.5 equivs) in dioxane (10 ml) was added to a stirred suspension of H-Tyr(Bu t)-OH. 
0.75H20 (502 mg, 2 mmol) in water (10 ml). Bnpeoc-ONSu (860 mg, 2 mmol) was then added 
and the mixture stirred for 16 hours at room temperature. The resultant solution was then diluted 
with water (20 ml) and the pH adjusted to 3.0 by the addition of KHSO 4 (2.0 M). The solution was 
extracted with ethyl acetate (3 x 100 ml) and the combined organic phase washed with water (3 
x 300 ml) and brine (1 x 200 ml), dried (MgSO 4) and the solvent removed in vacuoto give a clear 
oil which was crystallised from diethyl ether/light petroleum (b.p. 40-60 °C) to give the We 
compound (823 mg, 75%) as a white solid: m.p. 73-76 °C; (Found C, 60.8; H, 5.3; N, 7.6. 
C28HN3O9 requires C, 61.0; H, 5.3; N, 7.6%); tIc -E, R 0.65; h.p.l.c. -A, R t  24.2 min;[aJ 0 -20.0° 
(C 0.8 in DMF); Vm(CH2Cl2)  3420 (NH), 2985 (CH2 and CH3), 1760 (sh, carboxylic acid), 1720 
(s,urethane), 1610(phenyl), 1525(NO 2), 1505,1390, 1370(But),  1350(NO2), 1160,1110,1040, 
860, 830; X(MeOH) 276 (e 25000); H  (80 MHz; CDCI 3) 1.30 (9H, s, 3 x CH3 , But),  3.02 (2H, 
m, 13CH 2, Tyr), 4.4-4.8 (411, m, CHCH2, Bnpeoc and aCH, Tyr), 5.07(1 H, d, aNH,Tyr), 6.75-7.05 
(4H, m, Ar-H, Tyr), 7.35 (4H, d, Ar-H, Bnpeoc), 8.15 (41-1, d, Ar-H, Bnpeoc); &. (50 MHz; CDCI 3) 
28.65 (3 x CH 3 , But),  36.71 (pCH2, Tyr), 49.65 (aCH, Tyr), 5452 (CH, Bnpeoc), 65.86 (CH 2 , 
Bnpeoc), 78.65 ((CH 3)3), 123.93, 124.13, 129.09, 129.53 (Ar CH's, Bnpeoc and Tyr), 130.09, 
146.70, 147.07, 154.36 (quaternary C's, Bnpeoc and Tyr), 155.22 (urethane), 175.52 (carboxylic 
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acid); m/z: 551 (MH, 0.6%), 536(1.2), 496 (M+BUt,  12.1), 450 (4.8), 271 (13), 225 (20), 180(25), 
136 (38), 107 (100), 89 (23), 77 (24), 58 (100); hrms: found 550.18257. C 28H2809N3 requires 
550.18254. 
The title compound was prepared by route 1 and was crystallised from dichioromethane/diethyl 
ether as a white solid (87%); m.p. 114-115°C; (Found: C, 60.7; H, 4.8; N, 8.3. CHN4011 
requires C, 60.7; H, 5.05; N, 8.3%); tIc -E, R f 0.68; h.p.I.c. -A, R 1 24.8 mm; [a10  22 -2.1 0 (C 1.0 in 
DMF); Vm(CH2Cl2)  3420 (NH), 2840 (OCH3, Mbh), 1750 (sh, carboxylic acid), 1725 (s, 
urethane), 1685 (amide), 1610 (phenyl), 1525 (NO 2), 1515 (amide), 1350 (NO2), 1160, 1035,860 
(p. disubst. phenyl), 835; Am(CH2Cl2)  277 (c 20 500); H(200  MHz; CDCI3) 2.83 (2H, q, 1CH 2 , 
Asn), 3.72 (3H, s, CH 3O, Mbh), 3.74 (3H, s, CH 3O, Mbh), 4.44 (1 H, m, aCH, Asn), 4.5-4.8 (3H, 
br m, CHCH2, Bnpeoc), 6.00 (1 H, d, CH, Mbh), 6.08 (1 H, d, ex, aNH, Asn), 6.64 (1 H, d, 13CH 2 , 
Asn), 6.78-6.82 (4H, m, Ar-H, Mbh), 7.02-7.08 (4H, m, Ar-H, Mbh), 7.34 (4H, d, J8.78 Hz, Ar-
H, Bnpeoc), 8.12 (4H, d, J8.71 Hz, Ar-H, Bnpeoc);(50 MHz; CDI 3) 32.1 (CH2, Asn), 49.4 
((xCH, Asn), 53.4 (CH, Bnpeoc), 55.1 (CH 3O x 2, Mbh), 56.0 (CH, Mbh), 65.9 (CH 2, Bnpeoc), 
113.8, 123.9, 128.3,129.1 (aromatic CH's, Bnpeoc and Mbh), 133.2, 146.8, 158.6 (quaternary 
C's, Bnpeoc and Mbh), 155.8 (urethane), 172.1 (amide), 173.8 (CO 2H); m/z: 673 (MW, 0.7%), 
671 (1.0), 656 (1.4), 268 (7.0), 255 (10), 242(50), 227 (100), 213 (19); hrms: found 673.21453. 
CH35N4O11 requires 673.21456. 
' 
I S IJHI*li 
Bnpeoc-Lys(Boc)-OH,Dcha 
The title compound was prepared by route 2 as follows: triethylamine (0.76 ml, 5.5 mmol, 1.5 
equivs.) in dioxane (10 ml) was added to a stirred suspension of H-Lys(Boc)-OH (0.9 g, 3.65 
mmol) in water (10 ml). Tothis mixture was added solid Bnpeoc-ONSu (1.569, 3.65 mmol) and 
the mixture was stirred for 16 hours at room temperature. The solution was then diluted with water 
(30 ml) and the pH adjusted to 3.0 with KHSO 4 (2.0 M). This suspension was then extracted with 
ethyl acetate (3 x 150 ml) and the combined organic phase washed with water (3 x 250 ml) and 
brine (1 x 250 ml), dried (MgSO 4) and the solvent removed in vacuoto give a pale green gum. 
This was redissolved in dichioromethane (20 ml) and cooled to 0°C. Dicyclohexylamine (1.19 ml, 
1 equiv.) was then added and the solution stirred for 15 mm, after which diethyl ether (100 ml) was 
added to afford the title compound (4.12 g, 93%) as a white solid: m.p. 146-1 49°C(dec.); (Found 
C, 61.2; H, 7.4; N, 9.4. CH 55N5O10 requires C, 61.2; H, 7.4; N, 9.4%); [a]D  +2.90 (1.0 in DMF); 
tic -E, RO.55; h.p.l.c. -A, R24.8  mm; Vm  (CH2Cl2) 3440 (NH), 2970 (CH 2 and CH3), 2840, 1720 
(urethanes), 1635, 1610, 1600 (phenyl), 1525 (NO 2), 1395, 1365 (Boc Bu),  1350 (NO2); 
(MeOH) 275 (c 21 300); 8 H  (80 MHz; COd 3) 0.8 - 2.2 (37H, br m, CH 2 x 3, Lys, 10 x CH 2, Ocha, 
2x CH, Dcha, 3 x CH3, Boc), 3.0 (2H, m, cCH 2, Lys), 3.85(1 H, m, aCH, Lys), 4.55(3H, m, CHCH 2 , 
Bnpeoc), 5.65 (1H, aNH, Lys), 7.40 (4H, d, Ar-H, Bnpeoc), 8.10 (4H, d, Ar-H, Bnpeoc); S c 
(50MHz; CDCI3) 22.3 (CH2, Lys), 24.53 (2 x CH2, Dcha),25.00 (CH2, Lys), 28.26 (CH3 x 3, Boc), 
29.23 (CH2, Dcha), 32.99 (CH2, Lys), 40.42 (CH 2, Lys), 49.79 (aCH, Lys), 52.44 (CH, Dcha), 
55.52 (CH, Bnpeoc), 65.19 (OH 2, Bnpeoc), 78.84 ((CH3)3 , Boc), 123.85, 129.40 (Bnpeoc 
aromatic CH's), 146.92, 147.12 (Bnpeoc quaternary C's), 154.96, 155.78 (urethanes), 178.65 
(carboxylate); m/z: 743 (MH, 0.3%), 741 (0.76), 560 (0.21), 504 (0.4), 460 (2.1), 306(3.1), 182 
(100), 154 (23); hrms: found 742.40266. CHN 5O10 requires 742.40269. 
Bnpeoc-Lys(Boc)-OH 
Bnpeoc-Lys(Boc)-OH,Dcha (4.30g, 6.75mmol) was suspended in KHSO 4 (2.0 M, 500 ml) and 
extracted with ethyl acetate (3 x 300 ml). The combined organic phase was washed with water 
(3 x 500 ml) and brine (1 x 500 ml) and then dried (MgSO 4). The solvent was removed in vacuo 
and the residual oil redissolved in dichloromethane and evaporated in vacuo to give the title 
compound (3.36 g, 89%) as a yellow foam. A small quantitiy of the material was precipitated from 
chloroform/light petroleum (b.p. 40-60 °C) as a white amorphous powder: m.p. 76-79 °C; (Found 
C, 55.8; H, 5.8; N, 9.9. CH 32N4O 11 requires: C, 55.6; H, 6.1; N, 10.0%); tIc -E, R 1 0.55; h.p.l.c. 
-A, R t  24.8 mm; [a1D  +7.60 (c 1.0 in CHCI3); Vm(CH2Cl2)  3440 (NH), 2960 (CH 2 and CH3), 1720 
(S, urethanes and CO 2H), 1605, 1600 (phenyl), 1520 (NO 2), 1350, 1240, 1170, 1080, 870 (p.-
disubst. phenyl); (CHCI3) 275 (e 19500); 8H (80 MHz; CDCI3) 1.5 (1 5H, m, 3 x OH 3, Boc, 0, 
yand 8 OH 2, Lys), 3.05 (2H, m, eCH 2, Lys), 4.25(1 H, m, aCH, Lys), 4.63 (3H, m, CHCH 2, Bnpeoc), 
5.53 (1H, d, aNH, Lys), 7.37 (4H, d, Ar-H, Bnpeoc), 8.15 (5H, m, eNH, Lys and Ar-H, Bnpeoc); 
S. (50MHz; CDCI3) 22.06 (CH2 x 2, Lys), 28.04 (CH3 x 3, Boc), 31.24 (CH 2, Lys), 39.71 (CH2, Lys), 
49.48 (aCH, Lys), 53.47 (CH, Bnpeoc), 65.66 (CH 2, Bnpeoc), 79.30 ((CH3)3 , Boc), 123.77, 
129.04 (Bnpeoc aromatic CH's), 146.81 (Bnpeoc quaternary C's), 156.19 (urethanes), 175.52 
We 
(carboxylic acid); m/z: 561 (MH, 0.3%), 506 (MHFBut,  2), 254 (10), 178(8), 128 (17), 92 (17), 
85(25), 58(100); hrms: found 561 .21966. C 25HN4O10 requires 561 .21965. 
IM 
Bnpeoc-Aia-OH prepared by route 1 and crystallised from chloroform/diethyl ether to give the title 
compound (90%); m.p. 147-148°C (lit., 31 148-149.50C); [a] +0.80 (C 1.0 in DMF) (lit., 31 
1a10 +0.7°); tic -E, R 0.60; 8H [(CD3 )20; 200 MHz] 1.36 (3H, d, 3CH3), 4.20 (1 H, q, aCH), 4.70 
- 4.82 (3H, m, Bnpeoc CHCH2), 7.70, 8.22 (2 x 4H, 2 x d, Bnpeoc Ar-H); m/z: 404 (MH, 10%), 
257 (40), 62 (100). 
arginine cyclohexylamine salt 
Bnpeoc-Arg(Pmc)-OH ,Cha 
The title compoundwas prepared by route 2 and crystallised from dichloromethane /diethyl ether 
as a pale yellow solid (79%); m.p. 136-137°C;.(Found C, 57.8; H, 6.73; N, 11.6. C 41 HN7011 S 
requires C, 57.7; H, 6.5; N, 11.6%); tIc -E, RfO.4; Vm  (CH2Cl2) 3440 (NH), 1720 (urethane), 1610 
(phenyl), 1525 (NO2), 1350 (NO2); max  (MeOH) 435 (1200), 320 (13 600), 282(53 000), 256(48 
000); 6H  (80 MHz; COd 3) 1.0-1.9 (22H, br m, Pmc 2 x CH 3, Arg P and 1CH2's, Cha 5 x CH 2), 2.03 
(3H, s, Pmc CH3), 2.55 (2H, m, Pmc CH 2), 3.05 (3H, m, 6CH2, Arg and CH, Cha), 3.89 (1 H, m, 
Arg aCH, 4.5-4.7 (3H, m, CHCH 2, Bnpeoc), 6.0 -7.0 (7H, br m, Arg aNH, guanadino NH's, Cha 
NH3 ), 7.32 (4H, d, Ar-H, Bnpeoc), 8.10 (4H, d, ArH, Bnpeoc); m/z: 754 [Bnpeoc-Arg(Pmc)-OH, 
7.6%1, 366 (2.9), 326 (2.7), 219 (18), 203 (36), 147 (67), 100 (ChaW, 100). 
arginine 
Bnpeoc-Arg(Pmc)-OH 
The title compoundwas prepared by route 2 and precipitated from chloroform with light petroleum 
(b.p. 40-60°C) as a pale yellow solid: [75% from H-Arg(Pmc)-OH]; m.p. 120-140°C (lit., ca. 
140°C); (Found C, 55.3; H, 5.4; N, 10.8. Calc. for CH 42N6O 11 S: C, 55.7; H, 5.6; N, 11.1%); 
KII 
1a10 +3.60 (C 1.0 in CHCI3); m/z 755 (MW, 9%), 499 (5), 219 (20), 203 (50), 147 (100); hrms: 
found 755.271 04. C35H43N6011 S (MW) requires 755.271 03. 
We 
Bnpeoc-Asp(OBu t)-OH ,Dcha 
The title compound was prepared by route 2. The crude product formed a gel from dichlorom-
ethane/diethyl ether which was dried in vacuoto give a white solid which was then recrystallised 
from dichioromethane/diethyl ether (69%); m.p. 160-164°C; (Found C, 61.2; H, 7.0; N, 8.2. 
C35HN4O1Q requires C, 61.4; H, 7.1; N, 8.2%); tIc -E, R 0.66; h.p.l.c. -A, R 1 23.6 mm; ["J 
+17.8° (c 1.0 in CHCI3); Vm  3440 (NH), 2830,2730, 1725 (urethane), 1640, 1605, 1600 (phenyl 
and carboxylate), 1525 (NO 2), 1395, 1365 (teal. butyl), 1350 (NO2), 1150, 1080, 870, 830; 
(c 14600); 8H(80 MHz; CDCI3) 0.9-1.2 (20H, br m, lOx CH 2, Dcha), 1.38 (9H, 
s,3 x CH3 , tert. butyl), 2.73 (2H, m, 2 x CH, Dcha), 2.85 (2H, m, PCH 2, Asp), 4.05 (1 H, m, (xCH, 
Asp), 4.85 (3H, m, CHCH 2, Bnpeoc), 5.83 (1H, d, aNH, Asp), 7.38 (4H, d, Ar-H, Bnpeoc), 8.15 
(4H, d, Ar-H, Bnpeoc); & (50 MHz; COd 3) 24.39,29.92 (CH 2's, Dcha), 27.64(3 x CH 3 , tert. butyl), 
37.63 (CH2, Asp), 49.26 (aCH, Asp), 51.24 (2 x CH, Dcha), 53.03 (CH, Bnpeoc), 65.60 (CH 2 , 
Bnpeoc), 80.95 [(CH 3)3], 123.77, 129.50 (aromatic CH's, Bnpeoc), 146.81, 146.90 (quaternary 
C's, Bnpeoc), 155.16 (urethane), 170.24 (02But),  174.43 (CO2H); m/z: 685 (MH, 1.2%), 670 
(1.3), 491 (21), 426 (100), 399 (56), 288 (37), 271 (39), 255 (40); hrms: found 685.34482. 
CH49N4O10 (M H) requires 685.34484. 
The title compoundwas prepared by route 2 and precipitated as white solid from chloroform/light 
petroleum (b.p. 40-60 °C) (95%); m.p. 75-79°C; (Found C, 57.9; H, 6.50; N, 7.55. C 23H25 N3010 
requires C, 549; H, 5.01; N, 8.35%); tIc -E, R 1 0.66; h.p.l.c. -A, 1323.6  mm;  v(CH2Cl2)  3440 
(NH), 2960 (CH2, CH3), 2860 (CH), 1725 (urethane), 1610, 1600 (phenyl), 1525 (s, NO 2), 1390, 
1375 (tert. butyl), 1350 (NO2), 1230, 1150, 1070,870,830; max.(Me0F1)  277 (c 9700); oH  (80 
MHz; CDCI3) 1.36 (9H, ten'. butyl), 2.75 (2H, m, fCH 2, Asp), 4.32 (1 H, m, aCH, Asp), 4.63 (3H, 
CHCH2, Bnpeoc), 5.73(1 H, d, aNH, Asp), 7.37,8.15 (4H x 2, dx 2, Ar-H, Bnpeoc); 3c  (50 MHz; 
CDCI3) 27.66 (CH3 x 3, BUt),  37.09 (uGH2,  Asp), 49.47 (aCH, Asp), 52.53 (CH, Bnpeoc), 65.92 
91 
(CH2, Bnpeoc), 82.05 (Q(CH 3)3), 123.82, 129.04 (Ar CH's, Bnpeoc), 146.72, 146.87 (quaternary 
C's, Bnpeoc), 155.45 (urethane), 169.96 (.02BUt,  Asp), 174.86 (02H, Asp); m/z: 502(0.17%), 
448 (1.67), 426 (1.34), 271 (8), 186(16), 182 (100), 138(5), 134(7); hrms: found 504.16177: 
CHN3O, 0 (MH') requires 504.1 6180. 
The title compound was prepared by route 1 andcrystaiiised from acetone/light petroleum (b.p. 
40-60°C) as a white solid (94%): m.p. 189-190°C (lit., 3 ' 185-187°C); (Found C, 52.4; H, 4.5; N, 
11.9. Caic. for CHN3O9 C, 52.2; H, 4.4; N, 12.2%); tIc -F, R 1 0.6; S (50 MHz; [(CD)SO] 26.5 
(f3CH2, Gin), 31.3 (CH 2, Gin), 48.9 (aCH, Gin), 53.46(CH, Bnpeoc), 65.05 (CH 2, Bnpeoc), 123.6, 
129.5 (Bnpeoc Ar CH's), 146.4, 148.1 (Bnpeoc quaternary C's), 155.77 (urethane), 182.4 
(carboxylic acid). 
The title compound was prepared by route 1 and was crystaliised from THF/light petroleum (b.p. 
40-60°C) as a white solid (620/6); m.p. 97-107°C; (Found C, 60.5; H, 5.1; N, 7.9. C 35HN4O,, 
requiresC, 61.2; H, 5.0; N, 8.2%);tic-E, RO.66; h.p.i.c. -A R 24.9 min;[a] D22  +5.80 (ci .0 in DMF); 
v(CH2Cl2) 3420 (NH), 2740 (w, OCH 3, Mbh), 1740 (urethane and CO2H), 1670 (amide), 1610 
(phenyl), 1525 (NO 2 and amide), 1350 (NO2); (MeOH) 277 (c 23000); oH  (80 MHz; CDCI3 ) 
2.00 (21-1, m, 3CH 2, Gin), 2.25(21-1, m, 'CH 2, Gin), 3.71 (61-1, s,2 x OCH 3 , Mbh), 4.20 (1 H, m, aCH, 
Gin), 5.5 (31-1, br m, CHCH 2, Bnpeoc), 5.99 (21-1, m, aNH, Gin and CH, Mbh), 6.74 (41-1, d, JA13 8.7 
Hz, Mbh Ar-H), 7.05 (41-1, d, JAB 8.7 Hz, Mbh Ar-H), 7.30 (41-1, d, JAB  7.7Hz, Bnpeoc Ar-H), 8.10 
(41-1, d, JAB7•7  Hz); 8 (50 MHz; COd 3) 27.72 (GIn PCH2), 32.08 (GIn CH 2), 49.45 (Gin aCH), 
53.40 (Bnpeoc CH), 55.04 (2 x OCH3, Mbh), 55.96 (Mbh CH), 65.93 (Bnpeoc CH 2), 118.00, 
127.88, 128.29, 129.05 (aromatic CH's, Bnpeoc and Mbh), 133.25 (Mbh Ar4-C), 146.87 (Bnpeoc 
Ar 1-C and 4-C), 155.74 (urethane), 158.64 (Mbh Ar4-C), 172.64 (amide), 173.8 (carboxylic acid); 
m/z: 686 (MH, 73%), 669 (100), 578 (MH-PhOMe), 506 (42); hrms: found 687.23023. 
C35HN5O 1 , requires 687.23021. 
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Bnpeoc-GIu(OBu t)-OH ,Dcha 
The title compound was prepared by route 2. The crude product formed a gel from chloroform/ 
diethyl ether which was dried in vacuoto give a white solid which was then recrystallised from 
dichioromethane/diethyl ether (88 0/6); m.p. 129-132°C (lit., 31 124.5-1260C); (Found C, 61.5; H, 
7.25; N, 7.9. CaIc. for CHN 4O10 : C, 61.9; H, 7.2; N, 8.05); [aJ D +5.30 (C 1.0 in DMF) (lit., 31 
tic -E, A1 0.61, -G, A1 0.41; Vm  (CH 2Cl2) 3420 (NH), 2920 (CH 3 and CH2), 2870 
(CH), 1725 (urethane), 1640, 1620, 1595 (phenyl and carboxylate), 1525 (NO 2), 1490, 1350 
(NO2), 1160,860, 830; m/z: 699 (MH, 1.7%), 670(1.4), 491 (25), 462(30), 426(100), 254(58); 
hrms: found 699.36050. CaIc. for CHsiN4Oio(MH)  requires 699.36049. 
N'-[2 .2-bis(4 '-Nitrophenyl)ethoxycarbonyl] -'y- (tert.butyl)glutamic acid 
Bnpeoc-G l U (OBut)OH 
The title compound was prepared by route 2 and precipitated from chloroforrnllight petroleum 
(b.p. 40-60°C) as a white solid (82% from H-Glu(OBu t)-OH); (Found C, 55.2; H, 5.25; N, 8.1. CaIc. 
for C24H27N3O10 : C, 55.7; H, 5.2; N, 8.1); ?m  (MeOH) 275 (18 900); (80 MHz; CDCI 3) 1.40 
(9H, s, tert.butyl), 2.10 (2H, m, Glu 1CH 2), 2.25 (2H, m, Glu'H2), 4.29 (1H, m, Glu aCH), 4.5-
5.0 (3H, m, CHCH2, Bnpeoc), 5.5 (1H, d, aNH, Glu), 7.35 (4H, d, Bnpeoc Ar-H), 8.16 (4H, d, 
Bnpeoc Ar-H); m/z: 462 (40%), 416 (20), 271 (60), 254 (100), 225 (60), 179 (67); hrms: found 
518.17745. C24 1-1 28N30 11 requires 518.17745. 
IT 
The title compound was prepared by route 1 and was then precipitated from chloroform/ diethyl 
ether as a white powder (85%); m.p. 134-138°C; (Found 0,65.6; H, 4.5; N, 9.6; C 40HN5O8 .H2O 
requires C, 65.8; H, 4.8; N, 9.6%); tIc -E, R 1 0.65; 1aJ0 .i-4.40 (Cl .0 in DMF); Vm  (CH2Cl2) 3420 
(NH), 1760 (sh, carboxylic acid), 1720 (urethane), 1610 (phenyl), 1525 (NO 2), 1495, 1350 (NO2), 
1130,865, 850, 830; Xmx. (MeOH) 274 (c 23900); SH (80  MHz; COO13) 3.1 (2H, m, 3CH2, His), 
4.1 -4.7(4H, m, CHCH 2 , Bnpeoc and aCH, His), 6.05(1 H, d, aNH, His), 6.66(1 H, s), 6.9-7.5 (19H, 
m, Ar-H, Trt and Bnpeoc), 7.88(1 H, s), 8.1 0(4H, d, Ar-H, Bnpeoc), 9.75(1 H, brs, carboxylic acid); 
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(50 MHz; CDCI3) 28.71 (13CH2,  His), 49.58 (aCH, His), 53.73 (CH, Bnpeoc), 65.66 (CH 2 , 
Bnpeoc), 120.7-137.3 (9 peaks, trityl, His imidazole and Bnpeoc CH's), 146.75, 146.92 (Bnpeoc 
quaternary C's), 154.99 (urethane), 173.12 (carboxylic acid); m/z: 712 (MH, 2.5%), 470 (MW-
Trt, 2.3), 243 (Trt, 100), 165(52), 136(47), 77(30); hrms: found 712.24071. CHN 5O8requires 
712.24072. 
LI.Nlr!!1JI3Th 
The title compound was prepared by route 2 and crystallised from dichioromethane/diethyl ether 
as a white solid (920/6); m.p. 158-159°C (lit., 31 160-1620C); [a] D  +7.7° ( C 1.0 in DMF) (lit., 31  [aI0 
+7.7); tIc -E, R f U.50; ?m  (MeOH) 276 (e 20 300). 	 - 
I - [2 . 2-bis(4'-Nitrophenyl)ethoxycarbonytisoleucine 
Bnpeoc-1 Ie-OH 
The title compound was prepared by route 2 and precipitated from chloroform/light petroleum 
(b.p. 40-60°C) as a white amorphous powder (85% from H-Leu-OH); m.p. 59-62 °C; tIc -E, R, 0.5. 
N - [2 . 2-bis (4' Nitrophenyl)ethoxycarbonyl]leucine 
Bnpeoc-Leu-OH 
The title compound was prepared by route 1 and crystallised from chtoroform/diethyl ether (92 0/6); 
m.p. 68-70°C (lit., 31  67-71°C);[a]D  +4.90 (c 1.0 in DMF) (14.,31 [(X] 
27+41c). 
 8H (80 MHz; COOl3 ) 
0.87 (61-1, d, 2 x BCH3, Leu), 1.58 (31-1, m, 13CH 2 and 'yCH, Leu), 4.30(1 H, m, aCH, Leu), 7.38(41-1, 
d, Ar-H, Bnpeoc), 8.13 (41-1, d, Ar-H, Bnpeoc); mlz: 446 (MH, 20/6), 271 (20), 254 (20), 225 (27), 
178(30), 86 (37), 42 (90), 28 (100). 
Bnpeoc-Met-OH,Dcha 
The title compoundwas prepared by route 2 and crystallised from methanoVdiethyl ether as a pale 
yellow solid (81%); m.p. 186-189°C (lit., 31 179-180°C); (Found C, 59.3; H, 6.8; N, 8.7. CaIc. for 
C32H44N408S: C, 59.6; H, 6.8; N, 8.7%); tIc -F, R f  0.60; Vm(CH2Cl2)  3440 (NH), 2840 (CH2 and 
CH3), 2860 (CH), 1720 (urethane), 1640, 1610,1600 (phenyl and carboxylate), 1525 (NO 2), 1350 
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(NO2), 860, 830; 'max. (MeOH) 278 (c 17700); öH(360  MHz, CDCI3) 1.0-1.9 (20H, lOx CH 2 , 
Dcha), 2.0 (51-1, pCH 2, and GH3, Met), 2.43 (21-1, m, 'CH 2, Met), 2.73 (21-1, m, CH x 2, Dcha), 4.07 
(1H, m, aCH, Met), 4.5-4.7 (31-1, m, CHCH 2, Bnpeoc), 5.67 (1H, d, aNH, Met), 7.38 (41-1, d, Ar-
H, Bnpeoc), 8.15 (41-1, d, Ar-H, Bnpeoc); mlz: 399 (10), 182 (100), 98 (30), 83 (43), 56(70), 42 
(62). 
Bnpeoc-Met-OH 
The title compound was prepared by route 2 and was obtained as a foam from dichioromethane 
(78% from methionine); tic -F, R 0.6; 6H[80 MHz; (CD 3)2C0] 2.0 (obsc. by solvent, eCH 3 and 
CH2, Met), 2.5 (21-1, m, f3GH2, Met), 4.30(1 H, m, aCH, Met), 4.77 (31-1, m, CHCH 2, Bnpeoc), 7.70 
(41-1, d, Ar-H, Bnpeoc), 8.22 (41-1, d, Ar-H, Bnpeoc); m/z: 464 (11%),257 (30), 217(100), 199 (40), 
181 (90). 
If-[2 . 2-bis(4' Nitrophenyl)ethoxycarbonyfllohenylalanine 
Bnpeoc-Phe 
The title compound was prepared by route 1 and was recrystailised from diethyl ether to afford 
a white crystalline solid (93%); m.p. 77-80°C (lit., 3 ' 79-80 0C); (Found: C, 57.8; H, 4.5; N, 8.3. 
C24H21 N308.H20 requires C, 57.9; H, 4.6; N, 8.4%); [a] 0 -16.50 (c 1.0 in DMF) (lit.,3' [a]27.. 
15.7°); Sc  (50 MHz; CDCI3) 37.24 (CH2, Phe), 49.52 (aCH, Phe), 54.41 (CH, Bnpeoc), 65.73 
(CH2, Bnpeoc), 123.56, 127.11, 128.47, 129.01 (Ar CH's, Bnpeoc and Phe), 135,23 (Ar 
quatemary C, Phe), 146.64, 146.90 (Ar quaternary C's, Bnpeoc), 155.18 (urethane), 175.79 
(carboxylic acid). 
MIMI 
The solvent (0.5 ml) was vigorously stirred in a small (0.5 ml) reaction vessel (from a Wheaton 
Micro-Kit). An accurately weighed sample of the solid material (e.g. Bnpeoc amino acid) was 
added to the solution in small portions until either 0.25 mmol had been added or an insoluble 
precipitate had formed. The remaining sample was then weighed and the difference used to 
calculate the solubility. These are shown in table 6. 
Solubility in mmol/ml 








Bnpeoc-Gly-OH 0.06 0.14 (1:3) >0.6 
0.29(1:1) 
Bnpeoc-AIa-OH 0.05 0.50 (3:1) 
Bnpeoc-Arg(Pmc)-O >0.40 
Bnpeoc-Lys(Boc)-O >0.55 
Bnpeoc-Gly-OH >0 .5* 
Table 6. The solubility of some Bnpeoc amino acid derivatives. 
Notes 
*: in this case the DCM contained 0.5 mmoVml BOP reagent and 2 equivs. of DIEA 
The figures in parentheses indicates the ratio of the two solvents (e.g. dioxane:DCM) 
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3.5 Solid Phase Peptide Synthesis 
The preparation of all the peptides described in this section were carried out using an Applied 
Biosystems 430A automated solid phase synthesiser. All the solvents used were either freshly 
distilled (DCM) or used as commercially supplied by Applied Biosystems, Rathburn, or Aldrich 
(DMF). 
The C-terminal residue of those peptides with a C-terminal carboxylic acid (as opposed to 
a C-terminal amide) were coupled to the p-alkoxybenzyl alcohol resin outwith the synthesiser. The 
extent of this coupling was determined by deprotecting a small resin sample of known weight and 
measuring the absorbance of the olefin piperidine adduct produced using a UV spectrophotome-
ter. 
The following semi-permanant side chain protecting groups were used throughout: B u t 
ethers (Ser, Thr, Tyr); But  esters (Glu, Asp), Pmc (Arg), Trityl (His), Boc (Lys). Asn and GIn 
residues were used with no side chain protection unless otherwise stated. 
The syntheses were achieved using the following common procedures: 
Capping. Acetic anhydride (0.5 M in DMF, 3 ml) and pyridine (0.5 M in DMF, 3 ml) vortexed 
with the resin (6 mm). 
Washing. (5 x 1 mm, DMF). 
Removal of the Naprotecting  group. With 20% piperidine in DM F. The effluent from the reaction 
vessel was passed through a UV cell before being sent to waste. This allowed the efficiency of 
the peptide chain assembly to be monitored (30 mm). 
Washing. With the coupling solvent (either DCM or DMF, 4 x 1.5 mm). 
Activation. Carried out in the activator vessel. 
Coupling. Carried out in the reaction vessel. 
A variety of procedures were used for the activation and coupling of each residue and these 
are described in detail below. In double couple cycles steps 4, 5 and 6 are repeated at this stage. 
Washing. With DMF (x 5, DMF, 8 mm). 
The completed peptidyl resins were stored at -20°C, swollen in DMF with the last Nu_ 
protecting group uncleaved. This was removed, when required, by washing the resin in 20% 
piperidine in DMF [(10 ml for 5 mm) x 31 and washed with DMF (3 x 30 ml). 
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With diphenyiphosphinic anhydride 
During activation the Naprotected  amino acid (1.0 mmol), diphenylphosphinic anhydride 
(1.0 mmol) and NMM (1.0 mmol) in the coupling solvent (9 ml total volume) were mixed with a 
stream of nitrogen in the 'activator vessel'. During the coupling reaction, in which the activated 
amino acid derivative was vortexed with the peptidyl resin in the 'reaction vessel', NM M (0.5 mmol) 
and 2,6 lutidene (2.0 mmol) in the coupling solvent (3 ml total volume) were added. 
With the BOP reagent 56-58 
During activation the Naprotected  amino acid derivative (1.0 mmcl), BOP reagent (1.0 
mmol) and diisopropylethylamine (1.5 mmol) in the coupling solvent (9 ml total volume) were 
mixed in the 'activator vessel' (25 seconds) and then transferred to the 'reaction vessel' and 
vortexed with the peptidyl resin. 
With TBTU 59 
During activation the Nuprotected  amino acid derivative (1.0 mmot), TBTU (1.0 mmol), 
HOBt (1.0 mmol) and diisopropylethylamine (1.5 mmol) in the coupling solvent (9 ml total volume) 
were mixed in the activator vessel (25 seconds) and then transferred to the 'reaction vessel' and 
vortexed with the peptidyl resin. 
With diisopropylcarbodiimide 
During activation the Naprotected  amino acid derivative (2.0 mmcl) and diisopropylcar-
bodiimide (1.0 mmol) in the coupling solvent (9 ml total volume) were mixed in the 'activator 
vessel' by a stream of nitrogen gas for 15 min.The mixture was then transfrered to the 'reaction 
vessel' and vortexed with the peptidyl resin. 
With diisopropylcarbodiimide/1-hydroxybenzotriazole 
During activation the Naprotected  amino acid derivative (1 mmol), dilsopropylcarbodimide 
(1 mmcl) and HOBt (1 mmcl) in the coupling solvent (9 ml total volume) were mixed in the 'activator 
vessel' by a stream of nitrogen for 30 min.The mixture was then transfered to the 'reaction vessel' 
and vortexed with the peptidyl resin. 
ROTMOII I I Ri 	( I u1lT1Fiiil1iI.1t'ItU7 	 sIilM'4 FiiTI7Ii! 
Diisopropylcarbodiimide (0.48 ml, 3.05 mmol) was added to a stirred solution of Fmoc-Gly-OH 
(1.78 g, 6.0 mmol) in DMF (10 ml) at room temperature. After 10 min this solution was added to 
p-alkoxybenzyl alcohol resin (Bachem, 1.05 mmol/g) (1.439, 1.5 mmol), then DMAP (37 mg, 0.3 
mmol, 0.2 equivs.) was added and the mixture was agitated in an ultrasonic bath at room 
temperature for 3 hours. The resin was then filtered, washed with 0CM (3 x 30 ml), DMF (3 x 30 
ml) and diethyl ether (3 x 30 ml), and dried in vacuo. The coupling yield was found to be 34% (0.32 
mmol/g) by UV deprotection study 1 . The resin was then capped (see below). 
N9FIuorenylmethoxycarbonylalaninyl2methoxy4alkoxybenzyl alcohol resin (64) 
Fmoc-Ala-[O-CH 2-(2-OCH3) Ph( 1 ,4)-OR] 
Fmoc-Ala-OH.H 20 (1.32 g, 4 mmol) was dissolved in DMF (10 ml). To this was added 
diisopropylcarbodiimide (0.31 ml, 2 mmol) and OMAP (12.2 mg, 0.1 mmol). The reaction mixture 
was stirred at room temperature for 15 min and then added to 2-methoxy-4-alkoxybenzyl alcohol 
resin 127 ' 128 (Bachem, 0.945 mmol/g, 1.0 g). The mixture was then agitated in an ultrasonic bath 
for two hours, after which the resin was filtered, washed with DMF (3 x 10 ml) and diethyl ether 
(3 x 10 ml) and dried in vacuo. The coupling yield was found to be 75% (0.62 mmol/g) in a UV 
deprotection study' 26 and the resin was then capped (see below). 
S 
Bnpeoc-Gln(Mbh)-OH (1.38 g, 2 mmol) was dissolved in DM F and diphenylphosphinic anhydride 
(840 mg, 2 mmol) was added and the solution stirred for 10 mm. To this mixture was added N-
methylmorpholine (0.218 ml, 2 mmol), OMAP (12mg, 0.1 mmol) and p-alkoxybenzyl alcohol resin 
(Novabiochem, 0.79 mmol/g) (650 mg, 0.51 mmol). The mixture was agitated in an ultrasonic bath 
at room temperature for two hours. The resin was then removed by filtration, washed in DMF (3 
x 30 ml), DCM (3 x 30 ml) and diethyl ether (3 x 30 ml) and then dried in vacuo. The coupling yield 
was found to be 92% (0.49 mmol/g) in a UV deprotection study and the resin was then capped 
(see below). 
This procedure21 was carried out on each batch of resin functionalised with a benzyl alcohol type 
linker after the first amino acid had been coupled to it. As an example: the functionalised resin, 
Fmoc-Gly-(O-CH 2C6H4OR) (1.5 g; 0.32 mmollg) was suspended in dichlorornethane (30 ml) and 
cooled to 0°C with gentle stirring. Pyridine (0.5 ml) and benzoyl chloride (0.5 ml) were added. The 
resin was then agitated in an ultrasonic bath for 12 min at room temperature. The resin was then 
filtered, washed with dichloromethane (3 x 30 ml) and diethyl ether (3 x 30 ml). The resin was then 
dried in vacuo and stored at -20°C until required. 
Ubiguitin H-(residues 36-53)-OH (53). 
H-I Ie-Pro- Pro-Asp-Gln-Gln-Arg-Leu-lle-Phe-Ala-Gly-Lys-Gln-Leu-Glu -Asp-Gly-OH 
The synthesis was achieved using the functionalised resin (63), Fmoc-Gly-(O-CH 2C6H4-OR), on 
a 0.5 mmol scale employing NaFmoc  protected amino acid derivatives and diphenylphosphinic 
anhydride activation. Couplings were carried out in DMF, using a double couple cycle (2 x 2 
equ ivs. of mixed anhydride) except for glycine which was incorporated using a single couple cycle 
(1 x 4 equivs. mixed anhydride). 
The peptide was cleaved from the resin support with simultaneous removal of the side chain 
protecting groups by suspending an aliquot of the peptidyl resin in a mixture of TEA, water and 
thioanisole (10:1:1; 12 ml). The suspended resin was agitated in an ultrasonic bath for two hours, 
after which the resin was removed by filtration, washed with TEA (3 x 5 ml) and the combined 
filtrates were concentrated in vacuoto give a yellow oil. This oil was solidified upon adding diethyl 
ether (30 ml), to give the crude peptide (107.3 mg, 82%) as a white powder. An aliquot of this 
material (80.5 mg) was purified by preparative h.p.l.c. (gradient B) and the h.p.I.c. solvents were 
removed by lyophilisation to afford the We compound as a white solid (43.8 mg, 45%): h.p.l.c. 
-C, R t  15.6 mm; 6H(600  MHz; 90% H20/1 0% D20) tabulated below; m/z: 2026 (MW, 17%), 1645 
(5.2), 1233(26), 1007(29), 788(42), 732(100); hrms: found 2026.08026, CH 146N25O28 requires 
2026.08019; amino acid analysis: Asp 2 1.95, G1u4 3.96, Pro2 1.60, Gly2 2.09, Ala 1 1.02, lIe2 1.78, 
Leu 2 2.08, Phe 1 0.98, Lys 1 1.09, Arg 0.97. 
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Spin system aNH aCH PCH Others 
Ala 8.29 4.31 1.39 
AMX 1 8.53 4.60 2.85 
AMX 2 8.46 4.33 2.82, 2.93 
AMX 3 8.30 4.66 3.03, 3.16 
AM(PT)X 1 8.45 2.02, 2.11 2.57 
AM(PT)X 2. 8.36 2.02, 2.14 2.46 
AM(PT)X 3 8.26 2.06, 2.12 2.38 
AM(PT)X4 8.25 1.98, 2.19 2.38 
Gly 1 8.12 3.92 
Gly 2 7.95 3.95 
lie 1 4.17 1.79 
lie 2 7.97 4.10 1.79 CH2 1.40, 1.14 
CH3 0.81 
Leu 1 8.41 4.31 1.67 )CH 1.52, 2 x SCH3 0.93 
Leu 2 8.32 4.35 1.64 'CH 1.64, 2 x SCH 3 0.93 
Lys 8.14 4.29 1.76, 1.85 CH2 1.45, 8CH 2 1.43, 
eCH2 3.01, NH3 7.56 
Pro 1 4.43 2.11, 1.94 'CH2 2.05, SCH2 3.84, 3.62 
Pro 2 4.46 2.08, 1.97 'CH2 2.08, 6CH 2 3.87, 3.74 
Arg 8.21 4.28 1.82 'CH 2 1.64, SCH2 3.25 
6NH, 7.24 
Table 7. 1 1-1 spin systems assigned to the Ubiquitin fragment H-(residues 36-53)-OH. 
AM(PT)X systems are Glu and GIn, AMX systems are Phe and Asp72 
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LysinylthreoninylleucinylthreoniflylglyCyllySiflylthreOflifle amide (55) 
H-Lys-Thr-Leu-Thr-Gly-Lys-Thr-N H 2 
The synthesis was carried out using the functionalised resin Fmoc-NH-Dbs(5,2)-OCH 2Ph-R (5) 
(0.74 mmol/g, 0.66 g) on a 0.5 mmol scale employing N'1-Bnpeoc amino acid derivatives and the 
BOP reagent57' ( Penninsula) for activation. Couplings were carried out in dichloromethane 
using single couplings (1 x 2 equivs. activated amino acid derivative). 
The peptide was cleaved from the resin support with simultaneous removal of the side chain 
protecting groups by suspending an aliquot of the peptidyl resin (20% by weight) in a mixture of 
TFA, water and thioanisole (10:1:1, 12 ml). The suspended resin was agitated in an ultrasonic 
bath for two hours, after which the resin was removed by filtration, washed with TEA (3 x 5 ml) 
and the combined filtrates concentrated in vacuoto give a colourless oil. The crude peptide was 
precipitated as a white powder (72 mg, 96.5%) by the addition of diethyl ether (30 ml). An aliquot 
of this material (40 mg) was purified by preparative h.p.I.c. (gradient H) and the h.p.l.c. solvents 
were removed by lyophilisation to give the title compound(22 mg, 53%) as a white hygroscopic 
solid: h.p.l.c. -L, R 1 15.8 mm; [a]D-35.30(c  0.91 in H20); oH  (360 MHz; 90%H 20/10%D20) 0.92, 
0.98(2 x 3H, 2 x d, 2 x Leu OCH 3), 1.25 (9H, m, 3 x Thr 'CH 3), 1.48 (3H, m, Leu 'yCH and 
1.68-1.85 (1OH, m, 2 x Lys 3CH, 2 x Lys 'CH 2, 2 x Lys 5CH2), 1.95 (2H, m, 2 x Lys 3CH), 3.03 
(4H, m, 2 x Lys eCH 2), 4.0-4.6 (1OH, m, Gly CH 2, 5 x aCH, 3 x Thr 3CH), 7.17, 7.61 (2 x 1H, 
CONH2), 8.18,8.20, 8.31 (3 x 1H, 3 x d, 3 x aNH), 8.43 (1H, t, Gly aNH), 8.66,8.74(2 x 1H, 2 
x d, 2 x ctNH); m/z 747 (MH, 100%,), 728 (5), 702 (7), 434 (5). 374 (22), 246 (25); hrms: found. 
747.47284. C32HN10O10 (MH) requires 747.47283; amino acid analysis: Thr 3 2.87, G1y 1 1.00, 
Leu 1 0.95, Lys2 2.10. 
Ac-Lys-Thr-Leu-Thr-Gly-Lys-Thr-NH 2 
Peptidyl resin (20% by weight) from the synthesis of (55) was suspended in 20% piperidine in DMF 
[(10 ml for 5 mm) x 3] and washed in DMF (5 x 10 ml). The N-terminal amino group was then 
reacted with acetic anhydride (0.5 M in DMF, 10 ml) and pyridine (0.5 M in DMF, 10 ml) for 12 
min and then washed with DMF (5 x 10 ml). 
The peptide was then cleaved from the resin support and the side chain protecting groups 
removed simultaneously by suspending the peptidyl resin in a mixture of TFA, water and 
thioanisole (10:1:1, 12 ml). The suspended resin was then agitated in an ultrasonic bath for two 
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hours. The resin was then filtered, washed in TFA (3 x 5 ml) and the combined filtrates 
concentrated in vacuoto leave a colourless oil. The addition of diethyl ether (30 ml) precipitated 
the crude peptide as a white powder (70 mg, 89%). An aliquot of this material (30 mg) was purified 
by preparative h.p.l.c. (gradient H, A 1 10.0 mm) and the solvents removed by lyophilisation to 
afford the title compound(17.0 mg, 50%) as a white hygroscopic solid: h.p.l.c. -L, R 1 10.1 mm; 
I(XID22 0.52 in H20); H  (360 MHz; 90H200/0/1 0% 020)  0.92, 0.98 (2 x 3H, 2 x d, 2 x Leu 
6CH3), 1.10 (9H, m, 3 x Thr yCH 3), 1.4-1.6 (3H, Leu PCH 2 and 'CH), 1.65-1.95 (1 2H, m, 2 x Lys 
I, yand 8CH2), 2.09 (3H, s, acetyl CH 3), 2.99-3.12 (4H, m, 2 x Lys cCH 2), 4.0-4.5 (11 H, m, 6 x 
aCH, 3 x ThrCH, 1 x Gly CH 2), 7.07, 7.63(1 H x 2,s x 2, CONH2), 7.57 (6H, br, 2 x Lys eNH 3 ), 
8.13,8.21,8.24,8.28,8.34(5 x aNH), 8.42 (2H, m, Gly NH, 1 x aNH); m/z: 812 (MNa, 60%) 790 
(MH, 100), 385 (10), 357 (10), 272 (95), 254 (54), 215 (58); hrms: found 789.48342. 
CH65N 10011 (MW) requires 789.48339. 
Leucylglutamylaspartylçilvcylargininytthreoninvlleucine amide (57) 
H-Leu-Gtu-Asp-GIy-Arg-Thr-Leu-N H 2 
The synthesis was carried out using the functionalised resin Fmoc-NH-Dbs(5,2)-OCH 2Ph-
R (5) (0.74 mmol/g; 0.66 g) on a 0.5 mmol scale employing N'-Bnpeoc protected amino acid 
derivatives and diphenyiphosphinic anhydride activation. Couplings were carried out in DMF 
using a double couple cycle (2 x 2 equivs. of mixed anhydride) except for glycine which was 
incorporated using a single couple cycle (1 x 4 equivs. of mixed anhydride). 
The peptide was cleaved from the resin support and the side chain protecting groups 
removed simultaneously by suspending the peptidyl resin (160 mg) in a mixture of TFA, water and 
thioanisole (10:1:1; 12 ml). The suspended peptidyl resin was agitated in an ultrasonic bath for 
two hours, after which time the resin beads had taken on a deep red colour. The resin was then 
filtered, washed with TFA (3 x 10 ml) and the solvent removed from the combined filtrates in 
vacuo. Addition of diethyl ether (30 ml) precipitated the crude peptide as a white solid (32mg, 47%; 
amino acid analysis: Asp 1 0.99, Thr, 1.00, G1u 1 1.13, G1y 1 1.03, Leu2 1.84, Arg 1 1.00). 
This material was purified by preparative h.p.I.c. (gradient D) (R 1 11.0 mm) and the h.p.l.c. 
solvents removed by lyophilisation to afford the title compound (9.8 mg, 14.%) as a white solid: 
h.p.l.c. -E, R 1 11.0 mm; [a1022  -28.40 (C 0.37 in H20); H(600  MHz; D20) 0.93 (3H, d, Leu 8CH 3), 
0.98 (9H, m, 3 x Leu 8CH 3), 1.25 (3H, d, Thr)CH 3), 1.6-1.95(1 OH, m, 2 x Leu PCH2, 2 x Leu 'yCH, 
Arg PCH2, and Arg 'yCH 2), 2.06, 2.18 (2 x 1H, 2 x m, Glu PCH 2), 2.52 (2H, m, Glu 7CH 2), 2.95 
(2H, m, Asp PCH2), 3.25 (2H, t, Arg SCH 2), 4.0 (2H, d, Gly CH2), 4.09 (1 H, m, aCH), 4.38 (2H, 
m, 2 x czCH), 4.24 (1 H, m, Thr I3CH), 4.47, 4.49, 4.74 (3 x 1 H, 3 x m, 3 x aCH); m/z: 802 (MH, 
103 
100%), 757 (5), 399 (25), 329 (25), 165 (50); hrms: found 802.44225. CH 59N 11 O12 (MW) 
requires 802.44226; amino acid analysis: Asp 1 1.02, Thr1 0.97, Glu 1 1.03, Leu2 2.03, Arg 1 0.93 
Peptidyl resin from the synthesis of (57) was suspended in 20% piperidine in DMF [(10 ml for 5 
mm) x 3] and washed in DM F (5 x 10 ml). The N-terminal aminogroup was then reacted with acetic 
anhydride (0.5 M in DMF; 1 OmI) and pyridine (0.5 M in DMF; 10 ml) for 12 min and the resin was 
then washed with DMF (3 x 30 ml). 
The peptide was then cleaved from the resin support and the side chain protecting groups 
removed simultaneously by suspending the peptidyl resin in a mixture of TFA, water and 
thioanisole (10:1:1; 12 ml). The resin was stirred at room temperature for two hours after which 
the resin was filtered, washed with TEA (3 x 10 ml) and the solvent was then removed from the 
combined filtrates in vacuo. Addition of diethyl ether (30 ml) precipitated the crude peptide as a 
white solid (44 mg, 66%): amino acid analysis: Asp 1 0.98, Thr1 0.99, Glu 1 1.08, G1y1 1.01, Leu2 
1.93, Arg 1 1.01. This material was purified by preparative h.p.I.c. (gradient F) and two fractions 
were collected (R1  5.0 and 20.0 mm). The h.p.l.c. solvents were removed by lyophilisation to yield 
two white powders: the first material eluted was an impurity (5.7 mg, 8.5%) : 8H(600 MHz; D 20) 
0.93 (3H, d, Leu SCH3), 0.97 (3H, d, Leu 8CH3), 1.25 (3H, d, Thr)CH 3), 1.60 (1 H, m, Leu yCH), 
1.70 (4H, m, Leu PCH2 and Arg CH2), 1.78, 1.87(2 x 1 H, 2 x m, Arg pCH 2), 2.03, 2.18(2 x 1 H, 
2 x m, Glu PCH 2), 2.08 (3H, s, acetyl CH 3), 2.51 (2H, m, Glu 'CH 2), 2.93 (2H, m, Asp PCH2), 3.25 
(2H, I, Arg CH2), 4.00 (2H, m, Gly CH 2), 4.30 (2H, m, 2 x aCH), 4.37(1 H, d, Thr CH), 4.43,4.46, 
4.76 (3 x 1 H, 3 x m, 3 x aCH); m/z, 731 (100%), 687(5), 424(15), 329(20); amino acid analysis: 
Asp 1 0.98, Thr1 0.99, G1u 1 1.08, Gly 1 1.01, Leu 2 1.04, Arg 1 1.01; h.p.l.c. R  -G 15.2 mm) and the 
second material eluted was the title compound(14.9 mg, 22.3%): h.pJ.c -G, R t  20.2 mm; oH  (600 
MHz; H20) tabulated below; m/z 844 (MH 4 , 100%), 826 (10), 799 (11), 399 (7), 242 (8); hrms: 
found 844.45285. C35H62N 11 013 requires 844.45282; amino acid analysis Asp 1 0.92, Thr 1 0.93, 
G1u 1 1.10, Gly 1 1.00, Leu2 2.05, Arg 1 0.95. 
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Amino acid aNt-I aCH PCH Others 
Arg 8.04 4.44 1.81, 1.90 öCH2 3.23 
NH 7.21 
Asp 8.49 4.82 2.88, 2.97 
Glu 8.51 4.42 2.01, 2.15 2.48 
Gly 8.42 3.96 
Leu A 8.26 4.31 1.56 8CH3 0.89, 0.93 
Leu B 8.33 4.35 1.64 SCH3 0.89, 0.93 
Thr 8.25 4.35 4.21 'yCH3 1.22 
Ac CH3 2.05 
CONH 2 7.09, 7.59 
Table 8. 1 H resonances assigned from COSY experiments (20 mM, 90% H 2011 0% 020) 
lsoleucinylphenylalaninylalaninylglycvllysinylQlutamine (Ubiguitin residues 44-49) (54) 
H-I Ie-Phe-Ala-Gly-Lys-Gln-OH 
The synthesis was acheived using the functionalised resin Bnpeoc-Gln(Mbh)-(0-CH 2C6H4-OR) 
(65), on a 0.5 mmol scale employing NaBnpeoc  protected amino acid derivatives and diphenyl-
phosphinic anhydride activation. Couplings were carried out in DM F using a double couple cycle 
(2 x 2 equivs. of mixed anhydride) except for glycine which was single coupled (1 x 4 equivs. of 
mixed anhydride). 
The peptide was removed from the resin support with simultaneous removal of the side 
chain protecting groups by suspending the peptidyl resin (20% by weight) in a mixture of TEA, 
water and thioanisole (10:1:1, 12 ml). The suspended resin was agitated in an ultrasonic bath for 
two hours, after which the resin was removed by filtration and washed with TEA (3 x 10 ml). The 
combined filtrates were then concentrated in vacuo to give a pale yellow oil. Addition of diethyl 
ether (30 ml) precipitated the crude peptide as a white powder (67 mg, overweight). An aliquot 
of this material (40 mg) was purified by preparative h.p.l.c. (gradient J) and the h.p.l.c. solvents 
removed by lyophilisation to afford the title compound(22.1 mg, 59%) as a white solid: h.p.l.c. - 
M, R 1 8.5 mm; 5H(600  MHz, 90% H20/1 0% 020)  tabulated below; m/z: 664 (MH), 9%), 332 (3), 
105 
261 (5), 120 (20), 90 (30), 62 (55), 48 (82), 32 (100); hrms: found 663.38295. C 31 H51 N8014 
requires 663.38296; amino acid analysis: G1u 1 1.05, G1y1 1.03, Ala 1 0.97, lIe 1 0.95, Phe 1 0.99, 
Lys 1 1.07. 
Amino 
Acid 
aNH aCH J3CH Others 
lIe 3.86 1.99, 1.48 8CH3 0.93, TCH3 0.99 
'yCH 2 1.21 
Phe 8.72 4.71 3.11 2,4,6-H 7.33, 3,5-H, 7.39 
Ala 8.43 4.31 1.36 
Gly 7.59 3.89 
Lys 8.19 4.38 1.79, 1.89 CH2 1.48, 8CH2 1.71 
cCH2 3.02 
GIn 8.39 4.31 2.19, 1.99 'CH2 2.36 
Table 9. 1 H resonances of the hexapeptide (54) assigned from COSY and ROESY 
experiments (600 MHz; 90%H20/1 0%D20). 
Ac-Val-Tyr-Gln-Ser-Ala-1 le-Asn-Lys-Ala-lle-H is-Ala-Gly-Arg-Lys-lle-NH 2 
The title compound was prepared manually using a 'bubbler' reaction vessel, described by 
Atherton and Sheppard 106 , using the functionalised resin Fmoc-NH-Dbs(5,2)-OCH 2Ph-R (0.71 
mmoVg; 700 mg) (5) on a 0.5 mmol scale. Activation of the NaBnpeoc  amino acid derivatives was 
carried out with TBTU 59 ' 107 , with single couplings (1 x 2 equivs. of the activated amino acid 
derivative) except where a requirement for recoupling was indicated by the Kaiser test 108 . The 
following cycles required recoupling: 1 (lIe), 2 (Lys), 10 (Asn) and 15 (Tyr). All these second 
couplings were carried out with the BOP reagent 57 .58  The side chain amides of Asn and GIn 
residues were protected as their N-[bis-(4'-methoxyphenyl)methyl] derivatives [i.e. Bnpeoc-
Asn(Mbh)-OH and Bnpeoc-GIn(Mbh)-OH]. 
A studyof the deprotection of this peptide was undertaken, in which an aliquot of the peptidyl 
resin (30 mg) was suspended in a mixture of TFA, water, thioanisole and anisole (10:1:1:1, 13 
106 
ml) and agitated in an ultrasonic bath for tour hours. Samples of the reaction mixture were 
removed at hourly intervals, filtered, the solvent was removed in vacuo and diethyl ether (10 ml) 
was added to precipitate the crude peptide (approx. 3 mg). These were studied by analytical 
h.p.l.c. and mass spectrometry to determine the optimum time for deprotection which was three 
and a half hours. A larger batch of the peptidyl resin (250 mg) was then deprotected and the 
peptide cleaved from the resin support under the optimised conditions, then purified as detailed 
previously, to yield the crude peptide (105 mg, 75%). An aliquot (80 mg) of this material was 
purified by cation exchange chromatography on a CM-Sephadex column (2.5 x 25cm) eluting with 
ammonium acetate buffer (aq., 50 mM, pH 8.0) with gradient elution upto 700 mM. The fractions 
containing the major product were pooled and the solvents removed by lyophilisation to leave the 
partially purified peptide (29 mg, 27%). This material was further purified by preparative h.p.l.c. 
and the h.p.l.c. solvents were removed by lyophilisation to leave the title compound (9.2 mg, 
8.6%) as a white solid: 8H  (360 MHz; D20) 0.87-1.00 (24H, m, Val 8CH 3 x 2, lIe 8CH 3 x 3, lIe CH3 
x 3), 1.23 (31-1, m, 3 x lie CH), 1.42-1.54 (15H, m, Ala CH 3 x 2, lIe PCH x 3, lIe 'CH x 3), 1.70-
2.10 (19H, m, 2 x Lys ,y and ö CH 2, Val PCH, Gin PCHT  Arg P and 1CH2), 2.08 (31-1, s, Acetyl 
CH3), 2.8-3.4 (1 2H, m, 2 x Lys cCH 2, Arg 6CH2, Asn, His and Tyr 3CH 2), 3.70-4.60 (1 7H, m, 15 
x aCH, Ser 3CH2), 4.60 (1H, m, aCH), 6.88 (21-1, d, Tyr Ar-H), 7.18 (21-1, d, Tyr Ar-H), 7.38(1H, 
d), 8.70 (1 H, d); m/z 1810.9 (100%), 1646.8 (64), 905.4(91), 822.9 (48), 764.1 (27); hrms: found 
1810.04507. C81 H 137NO21 requires 1810.04509; amino acid analysis: Asp 1 1.07, Ser1 0.91, 
GIu 1 1.01, Gly, 1.12, Ala3 3.32, Va1 1 0.91, lIe3 2.56, Tyr 1 0.91, His 1 0.96, Lys2 2.14, Arg 1 1.06. 
N—Acetyl Cro (residues 15-37) amide (60) 
Ac-Giy-Gln-Thr-Lys-Thr-Ala-Lys-Asp-Leu-Gly-Val-Tyr-Gln-Ser-Ala-
lle-Asn-Lys-Ala-ile-His-Ala-Gly-N H 2 
Three comparative syntheses of this peptide were carried out and the differences are shown in 
table 10 below. Care was taken to ensure that the results were strictly comparable (for example, 
the same batch of functionalised resin was used for all three syntheses).The syntheses were 
carried out on a 0.2 mmol scale using the tunctionalised resin Fmoc-NH-Dbs(5,2)-OCH 2Ph-R 
(0.71 mmoVg; 280 mg) (5) with the Naprotected  amino acid derivatives and coupling procedures 
indicated. Couplings were carried out in DMF using a single couple cycle (1 x 5 equivs. activated 
amino acid). The removal of the Naprotecting  groups were monitored using a UV absorbance 
detector (ABI 757 absorbance detector) at 314 (Fmoc) and 405 nm (Bnpeoc) respectively. A 
portion of each of the peptidyl resins were suspended in a mixture of TEA, water, anisole and 1,2-
ethanedithiol (10:1:1:1; 13 ml) and agitated in an ultrasonic bath fortwo hours. The resin was then 
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removed by filtration, washed with TEA (3 x 5 ml) and then the combined filtrates were 
concentrated in vacuo. The crude peptide was then precipitated by the addition of diethyl ether 
(30 ml). An analytical h.p.l.c. trace of each sample was recorded and a small aliquot of the most 
successful synthesis (synthesis i) was purified by preparative h.p.I.c. (gradient J) and the h.p.l.c. 
solvents were removed by lyophilisation to leave the title compound(22 mg,38%) as a white solid: 
6H (600 MHz; CD3OH) tabulated below; rn/z 2412.8(100%), 2227.7 (19), 1371.5 (10),1206.9 
(25), 979.7 (30); hrms: found 2413.30316. C 105H175N320 (MW) requires 2413.3031 9: amino 
acid analysis: Asp2 2.09, Thr2 2.00, Ser1 0.91, G1u 2 2.04, Gly3 3.05, Ala4 4.36, Va1 1 0.98, lIe2 1.82, 
Leu 1 1.01, Tyr 0.82, His 1 0.83, Lys3 3.07 (mean deviationlresidue=0.056). 
Synthesis Protection Activation UV monitor Yield (%) 
Fmoc HOBt/DIC 314 nm 61 
ii Fmoc TBTU 314 nm 31 
iii Bnpeoc HOBt/DIC 405 nm 37 
Table 10. Yield is estimated from the peak areas observed with the UV monitored cleavage 
of the Naprotecting  group by 20% piperidine. The estimated error in these values is +1-5% 
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Amino acid aNH aCH PCH Others 
Ac CH3 2.04 
Glyl 5 8.55 3.85, 3.92 
Gln16 8.83 4.35 2.05, 2.15 TCH2 2.41, 
5NH2 7.06, 7.36 
Thrl7 7.99 4.04 4.30 yCH3 1.29 
Lys18 8.18 4.05 1.87, 1.95 )CH2 1.50, 
CH2 1.64, 1.77, cCH 2 2.96 
Thrl9 7.96 4.04 4.14 )CH 2 1.27 
A1a20 8.05 4.02 1.52 
Lys2l 7.99 4.05 1.97 )CH2 1.67, 8CH 2 1.48 
ECH 2 2.88 
Asp22 8.62 4.66 2.61, 2.95 
Leu23 8.36 4.21 1.68 CH 1.88, SCH 3 0.93, 0.96 
G1y24 8.28 3.94 
Va125 8.31 3.68 2.36 5CH3 0.96, 1.14 
Tyr26 8.21 4.23 3.18 3,5-H 7.01, 2,6-H, 6.66 
G1n27 8.79 3.88 2.12, 2.37 CH2 2.59, SNH2 7.41,6.72 
Ser28 8.20 4.23 4.03, 4.08 
A1a29 8.27 4.06 1.54 
11e30 8.12 3.68 1.92 yCH2 1.44, 1.10 
yCH3 0.69, 8CH 3 0.89 
Asn3l 8.32 4.43 2.96, 2.81 yNH 2 7.61, 6.92 
Lys32 8.28 4.03 1.93,1.99 CH2 1.47, SCH2 1.69 
cCH2 2.88 
A1a33 8.04 4.28 1.49 
1le34 8.22 3.85 1.92 CH2 1.60, 8CH3 0.83 
CH3 0.77 
His35 7.84 4.48 3.37,3.16 4-H 7.31, 2H 8.44 
A1a36 8.02 4.29 1.50 
G1y37 8.08 3.82, 3.90 Amide 6.81, 7.54 
Table 11. Assignment of the proton n.m.r. resonances for (62) in CD 3OH, taken from 
COSY, TOCSY and NOESY experiments. 
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The synthesis was carried out on a 0.25 mmol scale using the functionalised resin Na(9 
fluorenylmethoxycarbonyl)-alaninyl-2-methoxy-4-alkoxybenzyl alcohol resin (64)127.128(403  mg; 
0.62 mmol/g). Residues 29 to 66 were triple coupled using TBTU (3 x 2 equivs. activated amino 
acid) and residues 1 to 28 were double coupled with a symmetrical anhydride coupling (1 x 2 
equivs) followed by a DIC/HOBt coupling (1 x 2 equivs.). 
The peptide was cleaved from the resin with simuftaneous removal of the side chain 
protecting groups by suspending the peptidyl resin (20% by weight) in a mixture of TFA, 1 ,2-
ethanedithiol, water and anisole (10:1 :1:1; 13 ml). The suspended resin was agitated in an 
ultrasonic bath for 2 hours and the resin was then removed by filtration, washed with TFA and the 
combined filtrates were concentrated in vacuo to leave a pale yellow oil. Addition of diethyl ether 
(30 ml) precipitated the crude product as a white powder (259 mg, 88%) (table 12, column 2). A 
number of purification protocols were investigated and the success of the method assessed by 
amino acid analysis, SDS gel electrophoresis and analytical h.p.l.c. The crude peptide (120 mg) 
was applied to a Sephadex G50 (superfine grade) column (10 x 800 mm), previously equilibrated 
with ammonium acetate buffer (10 mM, pH 7.2). The required fractions were pooled and 
lyophilised in two major fractions (total 71.1 mg, 59%). The second (lowest molecular weight) 
fraction (15.5 mg, 12.9%) contained a major impurity: m/z: 2280 (100%), 1941 (56), 1835 (50); 
amino acid analysis: table 12, column 1. 
The other fraction (amino acid analysis: table 12, column 3) was further purified by cation 
exchange chromatography on a CM-Sephadex column (2.5 x 25 cm) eluting with buffer A 
(TrisHCl, 10 mM, NaCl, 100 mM, pH 7.9) for one column volume then gradient elution with buffer 
B (TrisHCl, 10mM, NaCl 1.OM, pH 7.9). The fractions were analysed by analytical h.p.l.c. and 
those containing the major component were pooled, lyophilised and desalted (Sephadex G1 5, 
2 x 100cm column) (3.1 mg, 2.5%): (amino acid analysis: table 12, column 4). The peptide was 
further purified by preparative h.p.l.c. (gradient J) then the solvents were removed by lyophilisa-
tion to give a white solid (1.1 mg): I H n.m.r (NaH 2PO4, 10 mM, pH 6.8) indicated the material was 
different from the material isolated from natural sources' 8991 ; m/z: (pdms) found 7365.7 (broad 
peak); required (Cr0 MH) 7352; amino acid analysis: table 12, column 5. 
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Expected 1 2 3 4 5 
Thr 6 2.09 4.75 5.06 5.83 5.33 
Ser 3 1.62 2.91 2.96 3.32 2.51 
Glu 6 2.33 5.80 5.66 7.19 6.00 
Pro 2 1.71 4.60 2.54 2.25 2.05 
Gly 4 1.25 3.08 3.99 4.18 4.85 
Ala 8 3.68 8.16 9.06 8.33 8.37 
Val 3 1.97 5.09 3.56 3.88 3.82 
Met 2 0.00 2.06 0.48 0.20 1.82 
He 5 0.82 3.80 5.17 4.41 5.00 
Leu 3 0.33 1.71 2.37 3.15 2.94 
Tyr 3 1.01 2.51 3.17 2.78 2.83 
Phe 3 1.52 3.00 3.15 2.87 2.98 
His 1 0.10 0.84 1.20 1.03 1.03 
Lys 8 3.46 7.68 7.56 7.93 7.54 
Arg 3 0.00 2.06 1.96 3.00 2.80 
Mean deviation/residue 0.18 0.13 0.11 0.07 
Table 12. Amino acid analyses taken throughout the purification. See the main text for 
details. Mean deviation per residue is the average difference between observed and expected 
values for all the residues. The analyser has an error of 3% (0.03) 
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